

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 February 2003 (27.02.2003)


PCT

(10) International Publication Number
WO 03/016495 A2

- (51) International Patent Classification⁷: **C12N** East Lincoln Avenue, Rahway, NJ 07065-0907 (US).
PETTIBONE, Douglas, J. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).
- (21) International Application Number: PCT/US02/26368
- (22) International Filing Date: 19 August 2002 (19.08.2002) (74) Common Representative: **HAND, J., Mark**; Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).
- (25) Filing Language: English
- (26) Publication Language: English (81) Designated States (*national*): CA, JP, US.
- (30) Priority Data: 60/313,531 20 August 2001 (20.08.2001) US (84) Designated States (*regional*): European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR).
- (71) Applicant (*for all designated States except US*): **MERCK & CO., INC.** [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). Published:
— *without international search report and to be republished upon receipt of that report*
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **HESS, John, W.** [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). **GOULD, Robert, J.** [CA/US]; 126

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TRANSGENIC RODENTS AS ANIMAL MODELS FOR MODULATION OF B₁ BRADYKININ RECEPTOR PROTEIN



NSE hB1 transgene

4132 bp

(57) Abstract: Transgenic rats are generated which incorporate a primate B₁ bradykinin receptor transgene(s) into their genome. This B₁ bradykinin receptor gene is expressed in these transgenic rats, which results in binding of compounds which are selective for the primate form (such as the human form) of the receptor and not the rat form of the receptor. Therefore, the expressed transgenes within these transgenic lines mimic antagonist and agonist selectivity of the wild type primate B₁ bradykinin receptor. These transgenic animals are useful as a specific receptor occupancy model for modulators of the B₁ bradykinin receptor from the human or closely related species, as well as providing for an animal model system for assessment of the pharmacodynamic properties of such a B₁ bradykinin modulator(s).

TITLE OF THE INVENTION

TRANSGENIC RODENTS AS ANIMAL MODELS FOR MODULATION OF
B₁ BRADYKININ RECEPTOR PROTEIN

5 CROSS-REFERENCE TO RELATED APPLICATIONS

Not Applicable

STATEMENT REGARDING FEDERALLY-SPONSORED R&D

Not Applicable

10

REFERENCE TO MICROFICHE APPENDIX

Not Applicable

FIELD OF THE INVENTION

15

The present invention relates to transgenic rodents which express a functional B₁ bradykinin receptor protein, preferably a mammalian B₁ bradykinin receptor protein and especially a functional non-human primate or human B₁ bradykinin receptor protein. The present invention is exemplified, but in no way limited by generation of transgenic rodents wherein random integration of a DNA sequence into the rodent genome has occurred, wherein the DNA sequence encodes the open reading frame of a human B₁ bradykinin receptor protein under control of a heterologous promoter. The present invention also relates to transgenic rodents which express functional modifications of a non-human primate or human B₁ bradykinin receptor protein, including but not limited to amino acid deletions, additions, substitutions, NH₂- or COOH-terminal truncations, splice variants, and the sort which provide for a protein with human B₁ bradykinin-like activity. The expressed transgenes within these transgenic lines mimic antagonist and agonist selectivity of the wild type B₁ bradykinin receptor. Therefore, the transgenic animals of the present invention are useful as a specific receptor occupancy model for modulators of a B₁ bradykinin receptor (such as a human B₁ bradykinin receptor), as well as providing for an animal model system for assessment of the pharmacodynamic properties of B₁ bradykinin modulators (e.g., human B₁ bradykinin modulators), such as antagonists or agonists of receptor activity.

20

25

30

BACKGROUND OF THE INVENTION

Dray and Perkins (1993, *TINS* 16: 99-104) and Proud and Kaplan (1988, *Annual Review Immunology* 6: 49-83) define two mammalian bradykinin receptor subtypes, B₁ and B₂, based on their pharmacological properties. The nonapeptide bradykinin (BK) and the decapeptide Lys-BK (kallidin) are liberated from the large protein precursor kininogen by the proteolytic action of kallikreins. BK and kallidin both activate the B₂ receptor. These B₂ receptor agonists are then degraded by a carboxypeptidase to produce the B₁ receptor agonists des-Arg⁹BK and des-Arg¹⁰kallidin or by the angiotensin converting enzyme (ACE) to yield inactive peptides. BK and kallidin act as equipotent agonists at the B₂ bradykinin receptor subtype. In contrast, BK is totally inactive at the B₁ bradykinin receptor subtype. Des-Arg¹⁰,Leu⁹[Kallidin] (herein, "DALK") is a peptide antagonist with structural similarities to kallidin.

The B₂ and B₁ bradykinin receptors are members of the superfamily of G-protein coupled receptors. Numerous mammalian B₁ and B₂ receptor genes have been isolated and characterized, including:

human B₁ bradykinin - U.S. Patent Nos 5,712,111 and 5,965,367, both issued to Menke et al. on January 28, 1998 and October 12, 1999, respectively, as well as Menke et al. (1994, *J. Biol. Chem.* 269:21583-21586).

rabbit B₁ bradykinin - MacNeil, et al., 1995, *Biochem. Biophys. Acta* 1264: 223-228.

mouse B₁ bradykinin - Hess et al., 1996, *Immunopharmacology* 33: 1-8;

rat B₂ bradykinin - McEachern, et al., 1991, *Proc. Natl. Acad. Sci.* 88, 7724-7728;

human B₂ bradykinin - Hess, et al. (1992, *Biochem. Biophys. Res. Comm.* 184: 260-268); and,

rat B₁ bradykinin - Jones, et al., 1999, *Eur. J. Pharmacol.* 374 (3), 423-433.

Hess et al. (1996, *Immunopharmacology* 33: 1-8) show that B₁ receptor agonist selectivity is species specific, namely when comparing the mouse, human and rabbit B₁ receptors.

Bock and Longmore (2000, *Current Opin. in Chem. Biol.* 4(4):401-407) present a recent update of known modulators of B₁ and/or B₂ bradykinin receptor activity. As reviewed by the authors, it is widely held in the scientific community that B₂ receptors, but not B₁ receptors, are expressed in normal tissue. In contrast,

biologic processes which result in inflammation, pain, tissue damage can rapidly induce B₁ receptor activity, as well as bacterial infection. The apparent inducibility of the B₁ receptor under such pathological conditions may provide a therapeutic window for the use of B₁ receptor antagonists as anti-inflammatory/analgesics, thus making the B₁ receptor an attractive drug target.

To this end, there remains a need for an animal model, including but not limited to a transgenic rat model, for use as a specific receptor occupancy model for modulators of the B₁ bradykinin receptor, as well as providing for an animal model system to assess pharmacodynamic properties of potential modulators for specificity to the human B₁ bradykinin receptor. The present invention meets this ongoing need by disclosing various transgenic rodent models which express a human B₁ bradykinin receptor protein.

SUMMARY OF THE INVENTION

The present invention relates to non-human transgenic animal cells, non-human transgenic embryos, non-human transgenic animals (including but not limited to founder animals) and/or non-human transgenic littermates, where one or more transgene(s) encoding a functional form of a non-native mammalian B₁ bradykinin receptor has been stably integrated into the germ cells and/or somatic cells of the non-human animal. Preferred non-human transgenic cells are rodent cells and a preferred non-native B₁ bradykinin receptor gene for stable integration into the rodent genome is a primate B₁ bradykinin receptor gene.

In an exemplified embodiment of the present invention, these non-human transgenic animal cells and embryos are rat cells and embryos, which subsequently give rise to a transgenic rat, including initial founder animals, littermates, and subsequent animals which comprise members of the stable transgenic line which expresses a functional form of the human B₁ bradykinin receptor. These transgenic animals contain a genetic modification such that the modified animal now expresses a functional protein which has the pharmacological properties of the human B₁ bradykinin receptor, i.e. membranes prepared from the brain of the transgenic animal (exemplified herein with transgenic rats) have pharmacological properties that are distinct from the respective non-transgenic animal.

The present invention preferably relates to animal cells wherein at least one transgene encoding a functional form of a human B₁ bradykinin receptor has been stably

integrated into the germ cells and/or somatic cells of the target animal. Additionally, the invention relates to non-human transgenic embryos, non-human transgenic founders, littermates and other transgenic animals which contain at least one transgene encoding a functional form of human B₁ bradykinin receptor. The transgenic animal cells, animals and littermates may express the non-native B₁ bradykinin receptor (e.g., a human B₁ bradykinin receptor) either in the presence or in the absence of the native (wild type) B₁ bradykinin receptor. In view of the methodology preferred for generating the transgenic rats of the present invention, a preferred transgenic cell, embryo and/or animal will contain alleles for both the native and transgenic, non-native B₁ bradykinin receptor.

10 The transgenic rat models as described herein will be useful to screen any potential modulator of receptor activity (e.g., antagonists or agonists), including but not necessarily limited to peptides, proteins, or non-proteinaceous organic or inorganic molecules. To this end, the present invention relates to processes for the production of the transgenic rats of the present invention and their offspring and their use for pharmacological testing. The invention further relates to methods of determining the selectivity and activity of potential modulators of the human B₁ bradykinin receptor by administering a test compound or compounds to the transgenic rat and measuring the effect of the compound on the activity of the human B₁ bradykinin receptor. To this end, the present invention relates to various occupancy assays with, for example, brain tissue, where the ability of a test compound to penetrate the blood brain barrier, distribute into the tissue and bind to the human B₁ receptor is measured.

25 As used herein, the term "functional" is used to describe a gene or protein that, when present in a cell or *in vitro* system, performs normally as if in a native or unaltered condition or environment. Therefore, a gene which is not functional (i.e., "non-functional", "disrupted", "altered", or the like) will encode a protein which does not function as a wild type, native or non-altered protein, or encodes no protein at all. Such a non-functional gene may be the product of a homologous recombination event as described herein, where a non-functional gene is targeted specifically to the region of the target chromosome which contains a functional form of the gene, resulting in a "knock-out" of the wild type or native gene.

30 As used herein, a "modulator" is a compound that causes a change in the expression or activity of a mammalian B₂ or B₁ bradykinin receptor, such as a human B₁

bradykinin receptor, or causes a change in the effect of the interaction of the respective receptor with its ligand(s), or other protein(s), such as an antagonist or agonist.

As used herein in reference to transgenic animals of this invention, we refer to "transgenes" and "genes". A gene is a nucleotide sequence that encodes a protein, or structural RNA. The gene and/or transgene may also include genetic regulatory elements and/or structural elements known in the art. As used and exemplified herein, a transgene is a genetic construct including a gene. The transgene is integrated into one or more chromosomes in the cells in an animal by methods known in the art. Once integrated, the transgene is carried in at least one place in the genome, preferably a chromosome, of a transgenic animal. The transgene of interest is incorporated into the target genome of the rat or other mammal, thus being introduced into their germ cells and/or somatic cells such that it is stably incorporated and is capable of carrying out a desired function. The transgene may also contain heterologous genetic regulatory elements and/or structural elements known in the art, such a heterologous promoter sequence and/or a heterologous enhancer sequence, which effects transcription of the open reading frame of the transgene within the target cell/animal. Such heterologous regulatory sequences are 'fused' or 'operatively linked' to the coding region so as to appropriately effect such gene expression. While a chromosome is the preferred target for stable incorporation of a transgene into the target animal, the term "genome" refers to the entire DNA complement of an organism, including nuclear DNA (chromosomal or extrachromosomal DNA) as well as mitochondrial DNA, which is localized within the cytoplasm of the cell. Thus, as noted previously, the transgenic rats of the present invention will stably incorporate one or more transgenes in either/or of the rat's germ cells or somatic cells (preferably both), such that the expression of the transgene (e.g., a functional form of a human B₁ bradykinin gene) achieves the desired effect of presenting a specific receptor occupancy model for modulators of the human B₁ bradykinin receptor as well as providing for an pharmacodynamic animal model system to study the selectivity of test compounds to modulate the human B₁ bradykinin receptor. It is preferable to introduce the transgene into a germ line cell, thereby conferring the ability to transfer the information to offspring. If offspring in fact possess some or all of the genetic information, then they, too, are transgenic animals.

As used herein, the term "animal" may include all mammals, except that when referring to transgenic animals, the use of this term excludes humans. It also includes an individual animal in all stages of development, including embryonic and fetal stages.

A "transgenic animal" is an animal containing one or more cells bearing genetic information received, directly or indirectly, by deliberate genetic manipulation at a subcellular level, such as by microinjection, targeted gene delivery such as by homologous recombination, or infection with recombinant virus. As noted above, this
5 introduced DNA molecule (i.e., transgene) can be integrated within a chromosome, or it can be extra-chromosomally replicating DNA.

As used herein, "rodent" relates to a species which is a member of the order Rodentia, having a single pair of upper and lower incisors for gnawing, wherein the teeth grow continuously and a gap is evident between the incisors and grinding molars.
10 Preferred examples include for generation of transgenic animals include, but are not limited to, *Rattus norvegicus*, *Rattus rattus*, and *Mus musculus*.

As used herein, "rat" relates to animals which from the point of systemic zoology belong to the genus *Rattus*. The transgenic animals of the present invention may be generated from any species of the genus *Rattus*, including but not limited to *Rattus*
15 *norvegicus* and *Rattus rattus*.

As used herein, "founder" refers to a transgenic animal which develops from the microinjected egg or target cell, such as an embryonic stem cell that has been targeted by a homologous recombination event to, for example, replace a rodent gene with its human homologue. The founders are tested for expression of a functional gene by any suitable
20 assay of the gene product.

As used herein, the term "line" refers to animals that are direct descendants of one founder and bearing one transgene locus stably integrated into their germline.

As used herein, the term "inbred line" refers to animals which are genetically identical at all endogenous loci. As used in the art, inbred lines may be used for including
25 reproducibility from one animal to the next, ability to transfer cells or tissue among animals, and the ability to carry out defined genetic studies to identify the role of endogenous genes. Such inbred lines may be developed from such lines wherein the rats that are used for microinjection are members of established inbred strains.

As used herein, the term "genotype" is the genetic constitution of an organism.

30 As used herein, the term "phenotype" is a collection of morphological, physiological and/or biochemical traits possessed by a cell or organism that results from the interaction of the genotype and the environment. Included in this definition of phenotype is a biochemical trait wherein a non-native transgene has been introduced into the animal, thus altering its the genotypic profile, and whereby

expression of this transgene(s) within the animal results in a new pharmacological selectivity to one or more chemical compounds, such a selectivity based on functional expression of the transgene(s) of interest. To this end, the term "phenotypic expression" relates to the expression of a transgene or transgenes which results in the production of a product, e.g., a polypeptide or protein, or alters the expression of the zygote's or the organism's natural phenotype.

As used herein, the terms "rat enolase promoter", "rat neuron specific enolase promoter", "NSE" and the such, are used interchangeably throughout this specification to refer to the promoter fragment used to exemplify the present invention, as discussed herein.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the transgenic plasmid targeting construct, ratEnolase intron A hB1 polyA2 [rat neuron specific enolase promoter_CMV intronA_human B1 bradykinin receptor coding sequence_BGH poly A signal CMV = human cytomegalovirus, BGH = bovine growth hormone (Construct #1; also referred to as NSE hB1)].

Figure 2A-B shows the nucleotide sequence of the integrated transgene, ratEnolase intron A hB1 polyA2, as shown pictorially in Figure 1A (SEQ ID NO:1).

Figure 3A-B shows the structure (Figure 3A) of the transcript generated from the ratEnolase intron A hB1 polyA2 targeting vector, also referred to as the NSE hB1 transcript, with the nucleotides sequence (Figure 3B) disclosed as SEQ ID NO:2.

Figure 4 shows the structure of the transgenic plasmid targeting construct, CMV promoter_CMV intron A_ human B1 cds_BGH.

Figure 5 shows a portion of the rat genomic plasmid targeting construct, CMV promoter_CMV Intron A_ hB1 cds_IRES2/LacZ_BGH poly A (also referred to as pCMV B1 IZ).

Figure 6A-B shows the nucleotide sequence of the integrated transgene CMV promoter_CMV Intron A_ hB1 cds_IRES2/LacZ_BGH poly A (SEQ ID NO:3).

Figure 7 shows a portion of the rat genomic plasmid targeting construct, Thy-1_hB1 cds- IZ pBS (also referred to as Thy1 hB1IZ).

Figure 8A-C shows the nucleotide sequence of the integrated transgene Thy-1_hB1 cds- IZ pBS (SEQ ID NO:4).

Figure 9A-C shows results from a saturation binding assay of ^3H -DALK ([des-Arg¹⁰, Leu⁹]-Kallidin) to membranes isolated from transgenic rat brain tissue from (A): line 0004 (rat #1810); (B): line 0014 (rat #1813); and (C): line 0015 (rat #1814).

5 Figure 10 shows autoradiograms of brain and spinal cord sections from NSE_hB1 line 0004 transgenic rats. Non-specific binding was determined with 0.3 nM [H-3] DALK in the presence of 200nM of a non-peptide antagonist of the human B1 bradykinin receptor that has sub-nM affinity for the human B1 receptor. Total binding was determined using 0.3 nM [H-3] DALK. Regions of the brain and
10 spinal cord that exhibit high levels of binding are indicated. Specific [H-3] DALK binding (total binding – nonspecific binding) is indicative of the level of human B1 bradykinin receptor expression. There is no detectable specific binding of [H-3] DALK in non-transgenic control rats.

15 DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to animal cells wherein at least one transgene encoding a functional form of non-native mammalian B₁ bradykinin receptor has been stably integrated into the germ cells and/or somatic cells of the target animal. To this end, the present invention relates to non-human transgenic embryos, non-human transgenic
20 animals and non-human transgenic littermates which contain at least one transgene encoding a functional form of a non-native, mammalian B₁ bradykinin receptor. Preferred non-human transgenic cells are rodent cells and a preferred non-native B₁ bradykinin receptor gene for stable intergration into the rodent genome is a primate B₁ bradykinin receptor gene. Example of various non-human primate sources for isolated
25 DNA molecules encoding B1 bradykinin receptor include but are not limited to members of the old world monkey group, such as various members of the genus *Macaca*, which included *Macaca mulatta*, the rhesus monkey; members of the new world monkeys such as members of the genus *Sanuinus*, which includes the tamarins; prosimians, which include *Lemur* members, and the great apes, such as the chimpanzee (*Pan troglodytes*),
30 orangutan (*Pongo pygmaeus*) and gorilla (*Gorilla gorilla*).

Therefore, the present invention relates to non-human transgenic animal cells, non-human transgenic embryos, non-human transgenic animals and/or non-human transgenic littermates, where one or more transgene(s) encoding a functional form of a non-native mammalian B₁ bradykinin receptor has been stably integrated into the germ

cells and/or somatic cells of the non-human animal. A preferred embodiment of this portion of the invention relates to transgenic rats which express a functional form of human B₁ bradykinin receptor, thus comprising rat transgenic cells and embryos, which subsequently give rise to a transgenic rats, including initial founder animals, littermates, and subsequent transgenic rats which represent a stable transgenic line expressing a functional form of the human B₁ bradykinin receptor. The transgene of interest contains a primate B₁ bradykinin receptor expression cassette operatively linked to regulatory sequences such as an enhancer and/or promoter fragment which are functional in the host animal, as well as a termination signal downstream of the B₁ open reading frame. The transgenic animal of the present invention allows for the investigation of pharmacological-based activity of an expressed transgene (e.g., human B₁ bradykinin receptor) in these animals, allowing for testing of the effect of certain test compounds within these transgenic animals and thus to perform preliminary tests for the development of new pharmaceutically active substances. It is evident from the data presented herein that non-human transgenic animals which incorporate a functional human B₁ bradykinin gene(s), or biologically equivalent form thereof, show a definable phenotype wherein the transgenic animal expresses an effective amount of the functional transgene product such that the transgenic animal now confers the selective pharmacological properties of the human B₁ bradykinin receptor. This phenotype is detailed herein via binding assays with membranes prepared from the brain of the transgenic rats, which are shown to have pharmacological properties that are distinct from the non-transgenic rats. This is evident in the binding data which demonstrates that human specific B₁ compounds, that have poor affinity for the rat B₁ receptor, have high affinity for membranes prepared from the brains of transgenic rats disclosed in the Example section. The endogenous rat receptor is unlikely to mask any phenotype. The radioligand ³H-DALK, has greater affinity for the human B₁ receptor than the rat B₁ receptor. This explains, in part, why no endogenous B₁ receptor activity is seen in non-transgenic rats using this ligand either by a whole brain homogenate assay or by receptor autoradiography of brain slices. In contrast, there is a binding site that is readily detectable using ³H-DALK in the exemplified transgenic rats expressing the human B₁ receptor using either of these techniques.

The transgenic rat models as described herein will be useful to screen any potential modulator of receptor activity (e.g., antagonists or agonists), including but not necessarily limited to peptides, proteins, or non-proteinaceous organic or inorganic molecules. The transgenic animals of the present invention provide for improved models

to study the *in vivo* effects of test compounds on human B₁ bradykinin receptor activity. Previous to this disclosure, treatments of test animal with an agent to increase wild type B₁ bradykinin expression (such as bacterial lipopolysaccharides) gave varying results to the extent in which B₁ bradykinin expression was increased and which altered the
5 properties of the blood-brain barrier. Even if successful, the properties of compounds selective for humans could not be assessed. To circumvent this problem, attempts were made to identify a species in which the pharmacological properties of the respective species matched the human B₁ bradykinin receptor; a disadvantage being that one species may have similar properties to the human with respect to one, but not all chemical series
10 under consideration. Alternatively, species that are closely related genetically to human (such as non-human-primates) can be used. However, this alternative suffers from the low throughput in assaying compounds through such a non-transgenic model, such as a non-human primate.

One such assay, provided only as an example and not as a limitation, is the use
15 of the transgenic animals of the present invention in an occupancy assay in the brain to assess the ability of test compounds to penetrate the blood brain barrier as well as the ability to distribute into the tissue and bind to the receptor. A type of occupancy receptor assay may be performed using the transgenic animal of the present invention and measuring the displacement of a known radiolabeled compound which binds to
20 the human B₁ bradykinin receptor. For example, male transgenic or non-transgenic Sprague Dawley rats may be dosed orally with test compound and fasted over night. On the day of the experiment body weights are obtained. Administration of 50%PEG/D5W vehicle (iv) or 1% methocell (po) is used to determine total binding. For iv dosed compounds, rats are placed in a perspex rat restrainer for tail vein
25 injection of vehicle, either a test compound and/or a second compound used for determination of non-specific binding. Seven and one-half minutes later, rats are returned to the restrainer and injected with 200 µCi/kg [³H]-test compound iv. For po dosed compounds, rats are dosed by gavage with vehicle or compound. Non-specific binding is determined. Sixty minutes later, rats are placed in the restrainer and
30 injected with 200 µCi/kg [³H]-test compound iv. Tail vein injections are through a 25 gauge, 1 inch needle on a 1 cc syringe. Tail veins are dilated by keeping rats warm and by wiping tails with an alcohol swab. Seven and 1/2 min after injection of isotope, animals are euthanized via CO₂ and the skull opened working from the base of the skull at the spinal cord opening forward to the orbital sockets. A slice of cortex

approximately 100-150 mg is cut and immediately placed in a pre-tared polypropylene tube and weighed. Cold HEPES buffer (10mM) [7.4 gms NaCl (150 mM), 4.8 gm HEPES (10 mM), 0.750 gm KCl (5 mM) per 2 liters of deionized water. pH brought to 7.4 with 1N NaOH. (NaCl & KCl: Fisher Scientific; HEPES (C₈H₁₈N₂O₄S: Boehringer Mannheim)] is added in 39 vols to each tube. Brains are homogenized using a polytron homogenizer at full speed for 10 sec. Five hundred μ l of homogenate are immediately filtered in duplicate through a 25mm Pall A/E filter (pre-soaked in 0.2% PEI) using a filter unit (Hoeffer). Homogenate is pipetted onto filters with valve closed so homogenate covers entire surface area of filter, valve is then opened to allow filtering and washing), followed immediately by 5 x 5 ml washes of cold HEPES (5mM KCl, 150 mM NaCl, 10 mM HEPES) buffer. Each filter is placed in a scintillation vial and Ultima Gold scintillation fluid (10 ml) is added to each vial. Duplicate 500 μ l aliquots of homogenate are pipetted into scintillation vials, 10 ml of Ultima Gold is added, and counted to measure total brain labelling. Samples are allowed to sit for 4 hours before counting with a tritium counting program. Isotope solution is counted with the tritium program to determine actual mCi concentration. A 0.001ml sample is pipetted into a vial containing 10 ml of scintillation fluid (pipet tip is carefully wiped with a kimwipe). Calculations are as follows: (1) Percent accumulation of label (% Acc) for each sample = (Filter dpm/Homogenate dpm)x100; (2) Percent specific accumulation (% Sp Acc) for the entire assay = Mean % Acc for Total Binding – Mean % Acc for Non-specific binding; (3) Percent inhibition of binding (% Inh) = ((Mean % Acc for Total Binding - % Acc for the sample))/ % Sp Acc)x100; (4) 1 μ Ci = 2.2 X 10⁶ DPM (0.001ml isotope solution(0.2mCi/ml) = 4.4 X 10⁵ DPM). Dose of the test compound may be 200 μ Ci/kg BW for dosing volume of 0.15 ml in 150 gm rat (0.2 mCi/ml): 1 ml of 1mC/ml (NEN) + 4 ml saline.

A preferred embodiment of the present invention is the generation of transgenic rodents in which one transgene encoding a functional form of a human B₁ bradykinin receptor has been stably integrated into the germ cells and/or somatic cells of the target animal. However, the present invention relates to the generation of other transgenic, non-human animals, other than the preferred targets of rats and mice, which exhibit substantially similar phenotypic traits as the exemplified transgenic rats disclosed herein, including but not limited to cows, pigs, rabbits, guinea pigs, sheep, hamsters, and goats.

Also, the present invention preferably relates to animal cells wherein at least one transgene encoding a functional form of a human B₁ bradykinin receptor has been stably integrated into the germ cells and/or somatic cells of the target animal. Additionally, the invention relates to non-human transgenic embryos, non-human transgenic animals and non-human transgenic littermates which contain at least one transgene encoding a functional form of human B₁ bradykinin receptor. The transgenic animal cells, animals and littermates may express the non-native B₁ bradykinin receptor (e.g., a human B₁ bradykinin receptor) either in the presence or in the absence of the native (wild type) B₁ bradykinin receptor. In view of the methodology preferred for generating the transgenic rats of the present invention, a preferred transgenic cell, embryo and/or animal will contain alleles for both the native and transgenic, non-native B₁ bradykinin receptor. Typically, the transgene of interest contains a human B₁ bradykinin receptor expression cassette linked to regulatory sequences such as an enhancer and/or promoter fragment which are functional in the host animal, as well as a termination signal downstream of the B₁ open reading frame. In the preferred mode of generating a transgenic rat encoding human B₁ bradykinin receptor, the transgene is typically integrated into a host chromosomal location by nonhomologous integration. These transgenes may further comprise a selectable marker, such as a neo or gpt gene operably linked to a constitutive promoter, such as a phosphoglycerate kinase (pgk) promoter or HSV tk gene promoter linked to an enhancer (e.g., SV40 enhancer).

In some embodiments, such as the targeted insertion of the human B₁ bradykinin gene into mice, the endogenous nonhuman B₁ alleles are functionally disrupted so that expression of endogenously encoded murine B₁ is suppressed or eliminated, so as to not interfere with expression of the human B₁ transgene. Transgenes may be incorporated into embryonic, fetal or adult pluripotent stem cells (Capecchi, 1991, Science 244: 1288-1292, see also U.S. Patent Nos. No. 5,464,764; 5,487,992; 5,627,059; 5,631,153 and 6,204,061 issued March 20, 2001) hereby incorporated by reference. Embryonic stem cells can be isolated from blastocysts cultivated *in vitro* and stably cultured within differentiation. For example, a transgene may be contained within a gene targeting vector, wherein the vector contains homologous arms (see Capecchi, *supra*) which can be used to direct a transgene to a specific genomic site within the target ES cell. Such foreign DNA can be incorporated into the embryonic stem cells by electroporation. Embryonic stem cells which carry the transgene in the appropriate fashion are injected into the inner cell

mass of blastocysts. A chimeric animal is generated which is then crossbred to obtain animals wherein all cell carry the transgene. Along with microinjection described below, ES cell-based techniques are a preferable methodology for generating transgenic mice. A common scheme to disrupt gene function by gene targeting in ES
5 cells is to generate a targeting construct which is designed to undergo a homologous recombination with its chromosomal counterpart in the ES cell genome. The targeting constructs are typically arranged so that they insert additional sequences, such as a positive selection marker, into coding elements of the target gene, thereby functionally disrupting it. To this end, the present invention also relates to methods of
10 producing nonhuman animals (e.g., non-primate mammals) that have the endogenous B₁ gene inactivated by gene targeting with a homologous recombination targeting construct. General principles regarding the construction of targeting constructs and selection methods are reviewed in Bradley et al., 1992, *Bio/Technology* 10: 534, which is hereby incorporated herein by reference.

15 It is within the scope of the present invention to present a transgene encoding a mammalian form of interest to the host target cell as a DNA construction such that expression of the respective B₁ bradykinin receptor is controlled by various homologous or heterologous regulatory sequences operatively linked to the B₁ bradykinin gene. To present as examples, but certainly not as a limitation, see
20 Figure 1 (rat neuron specific enolase [NSE] promoter and CMV Intron A fused (i.e., operatively linked) to the human B₁ bradykinin receptor gene, which is upstream of the bovine growth hormone (BGH) transcriptional termination and polyadenylation signal). Animals which integrate this construct will present neuron specific expression within the central nervous system. In contrast, peripheral expression of the
25 human B₁ bradykinin gene will occur via the integration construct shown in Figure 4 (CMV promoter/Intron A fused to the human B₁ bradykinin receptor gene, which is upstream of a second open reading frame (LacZ) which is separated by an internal ribosome entry site (IRES), with a BGH termination signal downstream of the LacZ ORF). Also, the transgene construct shown in Figure 7 (Thy-1 promoter fused to the
30 human B₁ bradykinin receptor gene, which is upstream of a second open reading frame (LacZ) which is in turn separated by an internal ribosome entry site (IRES), with a BGH termination signal downstream of the LacZ ORF) should promote brain specific expression. These various constructions show that any of a myriad of promoter/transgene constructions may be generated for transfer into target cells for

stable, genomic DNA integration and subsequent manipulation to produce a requisite transgenic animal. The exemplified constructs described herein also provide for the integration of discistronic constructs into a non-human transgenic animal. A preferred discistronic construct utilizes an internal ribosome entry site (IRES) to separate the
5 respective open reading frames (ORF). It is preferred that a first ORF encode for a functional form of a primate B₁ bradykinin receptor while a second ORF encode a reporter gene which allows for easy detection of tissue and/or cellular specific expression. Various reporter genes are well known in the art and include, as an example but certainly not a limitation, LacZ, green fluorescent protein (GFP),
10 chloramphenical acetyl transferase (CAT), alkaline phosphatase and luciferase.

A preferred method of generating a transgenic rat generally comprises first introducing DNA which includes the selected transgene into germ cells of the rat (typically fertilized eggs). These fertilized germ cells are then used to generate a complete, transgenic animal. The DNA is preferably introduced into the germ cells
15 by known microinjection techniques, which comprises introducing the DNA into a germ cell through the aid of a microscope and a microinjector pipette which deposits intact DNA into one of the two pronuclei. Transgenic animals are selected which have incorporated into their genome at least one, and possibly more than one, selected transgene(s). At least one founder transgenic rat is selected for breeding so as to
20 establish at least one transgenic rat line which contains the stably integrated transgene. This methodology is disclosed in U.S. Patent No. 4,873,191. Other known techniques available in the art may be utilized to generate the transgenic animals of the present invention, including but not limited to *in vitro* fertilization using sperm as a carrier of exogenous DNA, electroporation or alternatively, transfection into a rat
25 embryonic stem cell line may be utilized to directly target the transgene into the rat genome, followed by selection and introduction of selected, recombinant ES cells into a rat blastocyst.. Various methodology is reviewed in Mullins, et al., in *Transgenic Animal: Generation and Use*, Ch. 2.-Transgenic Rats, pp.7-9, Harwood Academic Publisher, 1997. Therefore, a preferred and well known method for preparing
30 transgenic rats of the present invention includes the following steps: subjecting a female to hormonal conditions to promote superovulation (with a continuous infusion of a follicle stimulating hormone), fertilization of the superovulated female (preferably by either breeding with a fertile male or via artificial insemination), introduction of the transgene into the fertilized eggs by known techniques, such as

microinjection; implantation of the fertilized eggs into a pseudopregnant female rat, who is then brought to term. Once the fetuses in the pseudopregnant female have been brought to term, a founder animal is identified by standard techniques of hybridization of transgene DNA to genomic DNA from weanling offspring or by a
5 PCR assay that is specific for the presence of the transgene. Founders that express the gene, particularly those that express the gene at levels and with the intended tissue distribution (such as brain specific expression) are selected and bred to establish the intended line or lines of transgenic rats.

It will be appreciated upon practicing the present invention that not all
10 transgenic animals which have an incorporated human B₁ bradykinin gene will exhibit appropriate expression of the B₁ genes of interest. For instance, data presented in Examples 3 and 6 show variable binding of ³H-DALK to the human B₁ bradykinin receptor on three separate transgenic rat lines expressing the human B₁ bradykinin receptor. Identifying an appropriate transgenic line may also be construct specific,
15 such a differences in promoter strength, number of transgenes incorporated into the genome, as well as the location of these integration events. The rat B₁ receptor is normally expressed at a much lower level than the transgene but its expression can be induced by certain treatments, e.g. lipopolysaccharide or streptozocin. As shown herein when comparing transgenic to non-transgenic rats, the rat B₁ bradykinin
20 receptor has pharmacological properties that are distinct relative to the human receptor, i.e. many synthetic compounds that have high affinity for the human B₁ receptor have low affinity for the rat B₁ receptor. Animals which express the transgene at sufficient amounts under normal conditions are especially useful in receptor occupancy assays. Animals which have expression levels similar to or
25 greater than line 0004, as measured in whole tissue assays, are preferred. However, lines with lower tissue expression (such as lines 0014 and 0015) may be useful if, for example, expression is localized within a discrete region of the tissue which is amenable to further study. To this end, one of ordinary skill in the art can expect to generate from about 6 to about 10 or so lines to be ensured that at least one of the
30 resultant lines will exhibit the desired trait. It may also be useful to identify and breed animals which have multiple copies of the human B₁ bradykinin incorporated into the target genome, such as from 2 to about 50 copies of the selected transgene. Therefore, it is within the purview of the present invention to characterize a specific transgenic animal to find a best fit for *in vivo/ex vivo* assays to determine binding

and/or receptor occupancy characteristics of for a specific test compound, wherein a specific binding/pharmacological profile will exist for the test compound in regard to the native and transgenic B₁ bradykinin receptor protein.

The nomenclature used herein and the laboratory procedures in transgenic protocols, cell culture, molecular genetics, and molecular biology are well known and commonly employed in the art. Standard techniques are used for recombinant nucleic acid methods, polynucleotide synthesis, cell culture, and transgene incorporation (e.g., electroporation, microinjection, lipofection). Various enzymatic reactions, oligonucleotide synthesis, and purification steps are performed according to the manufacturer's specifications. The techniques and procedures are generally performed according to conventional methods in the art and various general references which are provided throughout this document. The procedures therein are believed to be well known in the art and are provided for the convenience of the reader. All the information contained therein is incorporated herein by reference. The following examples are presented by the way of illustration and, because various other embodiments will be apparent to those in the art, the following is not to be construed as a limitation on the scope of the invention.

EXAMPLE 1

Construction of Transgenic Targeting Vectors

Construct #1 - ratEnolase intronA hB1 polyA2 vector -

[Step 1] - Rat genomic DNA (50 or 100 ng/50 ul reaction) was used as a template to generate a PCR fragment comprising the rat neuron specific enolase promoter region. Thirty two cycles of PCR were performed (94°C 25 sec, 60°C 25 sec, 68°C 3 min) with Expand High fidelity polymerase (Roche). The forward primer was: Rat_enl.2f: 5'-CATCACTGAGCCCAACACAA-3' (SEQ ID NO:5) and the reverse primer was Rat_enl.2r: 5'-TCACCTCGAGGACTGCAGAC-3' (SEQ ID NO:6). This PCR product was 2059 bp in length.

[Step 2] - The purified PCR product (Qiaquick PCR purification) from Step 1 was used as a template for a second round of PCR to add a BamHI restriction site. Thirty cycles of PCR (94°C 25 sec, 60°C 25 sec, 68°C 3 min) with Expand High fidelity polymerase using the following primers: Forward Rat_enl.4f, 5'-GCGGATCCTGAGCTCCTCCTCTGCTCGC-3' (SEQ ID NO:7); Reverse

NSE_1R, 5'-CTCGAGGACTGCAGACTCAG-3' (SEQ ID NO:8). The resulting product is 1814 bp in length.

[Step 3a] - A plasmid DNA template containing the CMVIntron A sequence was used as a template to generate a PCR fragment for subcloning. Twenty five
5 cycles (94°C 25 sec, 60°C 25 sec, 72°C 1 min) were performed using Pfu polymerase (Stratagene). The forward primer was CMVintA.1F:
5'-GTAAGTACCGCCTATAGAGTC-3' (SEQ ID NO:9) and the reverse primer is CMVintA.1R: 5'CTGCAGAAAAGACCCATGGAAAGG-3' (SEQ ID NO:10). This PCR product is 827 bp in length.

10 [Step 3b] - Twelve cycles of PCR were used (94°C 25 sec, 60°C 25 sec, 68°C 1 min 10 sec with either Pfu (Stratagene) or Expand High fidelity polymerase) to add overlap ends to the CMV intron A product of Step 3a. The forward and reverse primers are as follows: Forward:NSE_CMV.OLF1:
5'-GAGTCTGCAGTCCTCGAGGTAAGTACCGCCTATAGAGTC-3' (SEQ ID
15 NO:11);
Reverse CMV_hB1.OLR1:
5'-TGGCGGCGGTACCAAGCTTCTGCAGAAAAGACCCATGGAAAG-3' (SEQ ID NO:12). This PCR product is 863 bp in length.

[Step 4] - A PCR fragment comprising the human B₁ bradykinin receptor
20 coding sequence plus bovine growth hormone (BGH) polyA signal with overlap ends was constructed via 25 cycles of PCR (94°C 25 sec, 60°C 25 sec, 72°C 3 min) from plasmid pcDNA3 which contains the human bradykinin B₁ receptor sequence fused to the BGH poly A sequence. The primers were as follows:

Forward CMV_hB1.OLF1:
25 5'-CTTTCCATGGGTCTTTTCTGCAGAAGCTTGGTACCGCCGCCA-3' (SEQ ID NO:13);
Reverse: BGH.1RNot:
5'- GCGCGGCCGCTCCCCAGCATGCCTGCTATTG-3' (SEQ ID NO:14). This PCR is 1518 bp in length.

30 [Step 5] -The CMV intron A was combined with the with human B₁_BGH polyA fragments via 25 cycles of PCR (94°C 25 sec, 60°C 25 sec, 68°C 4 min 30 sec) using the templates purified from Step 3 and Step 4. The primers were as follows:
Forward NSE_CMV.OLF1:

5'-GAGTCTGCAGTCCTCGAGGTAAGTACCGCCTATAGAGTC-3' (SEQ ID NO:15);

Reverse: BGH.1RNot:

- 5'- GCGCGGCCGCTCCCCAGCATGCCTGCTATTG-3' (SEQ ID NO:14). The
5 PCR product of Step 5 is 2342 bp.

[Step 6] - The PCR product from step 2 was digested with Bam HI and the PCR product from Step 5 was digested with Not I. A three-way ligation was performed with BamHI/NotI digested pCR[®]-Blunt II-TOPO[®] vector (Invitrogen).

- DNA sequence analysis was performed to select clones containing the fewest
10 PCR errors. Selected clones were subcloned into BamHI/NotI digested pBlueScript (pBS) by 3-way ligation with the Bam HI/Afl II 2443 bp fragment and the Afl II/Not I 1699 bp fragment. The resulting transgene is shown in Figure 1 while the nucleotide sequence of transgene is shown in Figure 2A-B. A schematic of the transcript for this construct is shown in Figure 3A while the nucleotide sequence of the projected
15 transcript (shown as a DNA sequence) of the transcript is shown in Figure 3B.

Construct #2 - CMV promoter_CMV intron A_human B1 cds_BGH poly A signal vector -

- [Step 1- CMV promoter] One hundred nanograms of pcDNA3 was subjected to 18 cycles of PCR (94°C 25 sec, 60°C 25 sec, 72°C 1 min) with either Pfu or Expand
20 High Fidelity polymerase. The primers were as follows:

Forward CMV promoter 1F:

5'-CGGCGGCCGCGGATGTACGGGCCAGATATAC-3' (SEQ ID NO:16);

Reverse:

5'-GACTCTATAGGCGGTACTTACCTATAGTGAGTCGTATTAATTTTCG-3'

- 25 (SEQ ID NO:17). The resulting product is 702 bp.

[Step 2 - CMV intron A] - One hundred nanograms of a DNA plasmid template comprising the CMV Intron A fragment was subjected to 18 cycles of PCR (94°C 25 sec, 60°C 25 sec, 72°C 1 min) with Pfu polymerase. The primers were as follows:

- 30 Forward CMV promoter_intron A 1F -

5'-CGAAATTAATACGACTCACTATAGGTAAGTACCGCCTATAGAGTC-3' (SEQ ID NO:18);

Reverse CMVintA.1R -

5'-CTGCAGAAAAGACCCATGGAAAGG-3' (SEQ ID NO:10). The product is 850 bp in length.

[Step 3] The CMV promoter fragment was linked to the CMV intronA by subjecting the PCR products of Step 1 and Step 2 to 18 cycles of PCR (94°C 25 sec, 60°C 25 sec, 72°C 1 min 30 sec) with Pfu polymerase. The primers were as follows:
5
Template: 2 ng of each PCR product from step 1 and step 2

Primers: Forward CMV promoter 1F

5'-CGGCGGCCGCGGATGTACGGGCCAGATATAC-3' (SEQ ID NO:16);

Reverse CMVintA.1R

10 5'-CTGCAGAAAAGACCCATGGAAAGG-3' (SEQ ID NO:10). This PCR product is 1508 bp in length.

[Step 4] - The CMV promoter_CMV intron A_human B1 bradykinin receptor coding sequence_ BGH poly A signal was constructed by digesting the PCR product from Step 3 with Afl II (cuts in CMV intron A). The ratEnolase intronA hB1 polyA2
15 vector described in this Example was digested with EcoRV and Afl II and these digested fragments were ligated together to generate the transgene shown in Figure 4.

Construct #3 - CMV intron A:human B1 coding:IRES element:Lac Z: BGH poly A - The targeting vector as detailed in Figure 5 was generated as follows:

[Step 1] - The pIRES puro plasmid (Clontech) was used as a template to
20 generate a PCR fragment comprising the IRES element. The PCR reaction was carried out for 20 cycles (94°C 25 sec, 60°C 25 sec, 68°C 1 min 30 sec) with Expand High Fidelity polymerase.

Primers: forward HB1_IRES F-

5'-CCAACTTTTCTGGCGGAATTAATGCATCTAGGGCGGCCAATTC-3' (SEQ
25 ID NO: 19);

Reverse: IS_LACZ_1R -

5'-GTAAAACGACGGGATCTATCATGGTGGCGGCGGTTGGCAAGCTTATCATCGTG-3' (SEQ ID NO:20). The resulting product is 639 bp in length.

[Step 2]: The LacZ coding region was generated as a PCR fragment by utilizing
30 pcDNA3 beta-Gal plasmid DNA (Invitrogen) as template and running a PCR reaction for 28 cycles (94°C 25 sec, 60°C 25 sec, 68°C 3 min) with Pfu and Expand High Fidelity polymerase. The primers were as follows:

Primers: forward: IS_LACZ_1F -

5'-CACGATGATAAGCTTGCCAACCGCCGCCACCATGATAGATCCCGTC

GTTTTAC-3' (SEQ ID NO:21);

Reverse: 5'-GCCTCGAGCTATTTTTGACACCAGACCAACTG-3' (SEQ ID NO:22). The resulting product is 3098 bp in length.

[Step 3]: The PCR products of Step 1 and Step 2 were linked via 18 cycles of PCR (94°C 25 sec, 60°C 25 sec, 68°C 4 min) with Expand High Fidelity polymerase.

Primers: forward HB1_IRES F

5'-CCAACTTTTCTGGCGGAATTAATGCATCTAGGGCGGCCAATTC-3' (SEQ ID NO: 19)

Reverse: LZ_BGH R

5'-CATTTAGGTGACACTATAGAATCTATTTTTGACACCAGACCAACTG-3' (SEQ ID NO:23). The resulting product is 3721 bp in length.

[Step 4] - The BGH poly A signal is generated by PCR from the plasmid pcDNA3 (Invitrogen) via 18 cycles (94°C 25 sec, 60°C 25 sec, 68°C 4 min) with Expand High Fidelity polymerase. The primers are as follows:

Forward LZ_BGH F -

5'-CAGTTGGTCTGGTGTCAAAAATAGATTCTATAGTGTACCTAAATG-3' (SEQ ID NO:24);

Reverse: BGH.1RNot -

5'-GCGCGGCCGCTCCCCAGCATGCCTGCTATTG-3' (SEQ ID NO:14).

[Step 5] -The BGH polyA PCR fragment of Step 4 was linked to the IRES:LacZ fragment of Step 3 via 20 cycles of PCR (94°C 25 sec, 60°C 25 sec, 68°C 4 min 30 sec) with Expand High Fidelity polymerase. The primers are as follows: HB1_IRES F -

5'-CCAACTTTTCTGGCGGAATTAATGCATCTAGGGCGGCCAATTC-3' (SEQ ID NO:19);

Reverse: BGH.1RNot -

5'-GCGCGGCCGCTCCCCAGCATGCCTGCTATTG-3' (SEQ ID NO:14)

Product: 3963 bp

[Step 6] - The ratEnolase intronA hB1 polyA2 vector described in this Example was used as a template to generate a CMV intron A:human B1 coding sequence via 18 cycles (94°C 25 sec, 60°C 25 sec, 68°C 2 min 30 sec) of PCR, using the Pfu polymerase. The primers were as follows:

Forward CMVintA.1F - 5'-GTAAGTACCGCCTATAGAGTC-3' (SEQ ID NO:9);

Reverse: HB1_IRES R

5'-GAATTGGCCGCCCTAGATGCATTAATTCCGCCAGAAAAGTTGG-3' (SEQ ID NO:25). The resulting product is 1931 bp in length.

[Step 7] - The PCR products from Step 6 (CMVintron A: human B1 cds) and Step 1 (IRES) are used as a template to link these to DNA fragments by PCR.

- 5 Twenty cycles (94°C 25 sec, 60°C 25 sec, 68°C 4 min 30 sec) and Expand High Fidelity polymerase were utilized with the following primers:

Forward: CMVintA.1F

5'-GTAAGTACCGCCTATAGAGTC-3' (SEQ ID NO:9);

Reverse: IS_LACZ_1R

- 10 5'-GTAAAACGACGGGATCTATCATGGTGGCGGCGGTTGGCAAGCTTATCATCGTG-3' (SEQ ID NO:20). The resulting product is 2549 bp in length.

[Step 8]: The PCR products from Step 7 and Step 5 are used to link the CMVintron A: human B cds (Step 7) to IRES_LacZ_BGH poly A (Step 6) via 18 cycles (94°C 25 sec, 60°C 25 sec, 68°C 7 min 30 sec) of PCR. The primers

- 15 were as follows:

Forward: CMVintA.1F

5'-GTAAGTACCGCCTATAGAGTC-3 (SEQ ID NO:9)

Reverse: BGH.1RNot

- 20 5'-GCGCGGCCGCTCCCCAGCATGCCTGCTATTG-3' (SEQ ID NO:14). The resulting product is 5851 bp in length. This fragment is then subcloned into the DNA expression plasmid pCRII Topo Blunt (Invitrogen) and subjected to DNA sequence analysis to confirm generation of the appropriate transgene.

Construct 4 - CMV promoter:CMV intron A:human B1 coding:IRES2 element:Lac Z: BGH poly A -

- 25 [Step 1] A 520 bp Bgl II/Nsi I fragment from Construct 3 is subcloned into pIRES2-EGFP (Clontech). This subclone is digested with Bgl II/Nco I. A PCR fragment spanning a portion of LacZ is generated from a pcDNA3_beta Gal (Invitrogen) template via 37 cycles of PCR (94°C 25 sec, 60°C 25 sec, 68°C 2 min 30 sec) with Pfu polymerase. The primers were:

- 30 Forward: LZ_BspHI -

5'-GGCATCATGATAGATCCCGTCGTTTTAC-3' (SEQ ID NO:26);

Reverse: 5'- IZ_2699R

5'-TACTGTGAGCCAGAGTTGCC-3' (SEQ ID NO:27). The resulting product is 2081 bp in length. This product is digested with BspHI and EcoRV. This 1113 bp

fragment and the Bgl II/Nco I fragment above are ligated with Construct #2 and digested with Bgl II and EcoRV. The target transgene is shown schematically in Figure 5 and the nucleotide sequence of the transgene is shown in Figure 6A-B.

Construct #5 - Thy-1 promoter:human B1 coding:IRES2 element:Lac Z: BGH

5 *poly A -*

[Step 1] - A DNA fragment comprising the mouse Thy-1 promoter was generated from a PCR reaction using mouse genomic DNA as a template. The PCR reaction was carried out for 30 cycles (94°C 25 sec, 60°C 25 sec, 68°C 3 min 30 sec) with Expand High Fidelity polymerase. The primers were as follows:

10 Forward - Thy1_1f_Not:

5'-GCGCGGCCGCTCTGGTTATCCAGGCTTCTG-3' (SEQ ID NO:28);

Reverse - Thy1_hB1r:

5'-GGTGGCGGCGGTACCAAGCTTGTGCCAAGAGTTCCGACTTG-3' (SEQ ID NO:29). The resulting PCR product is 2923 in length.

15 [Step 2] - A portion of human B₁ Bradykinin coding sequence was generated from 10 ng human B₁ receptor cloned into pcDNA3. PCR conditions were as follows: 18 cycles of PCR (94°C 25 sec, 60°C 25 sec, 68°C 4 min) with Pfu polymerase. The primers were:

Forward - Thy1_hB1f:

20 5'-CAAGTCGGAAGCTTGGCACAAGCTTGGTACCGCCGCCACC-3' (SEQ ID NO:30);

Reverse: hB1_2r

5'-TGCTTGCACCTGGAATAAG-3' (SEQ ID NO:31). The resulting product was 881 bp in length.

25 [Step 3] -The PCR products from Step 1 and Step 2 were linked via a PCR reaction (18 cycles @ 94°C 25 sec, 60°C 25 sec, 68°C 4 min) with Expand High Fidelity polymerase. The primers were:

Forward - Thy1_1f_Not:

5'-GCGCGGCCGCTCTGGTTATCCAGGCTTCTG-3' (SEQ ID NO:28)

30 Reverse - hB1_2r:

5'-TGCTTGCACCTGGAATAAG-3' (SEQ ID NO:32). The resulting product is 3753 bp in length and was cloned into the TOPO TA vector (Invitrogen), followed by DNA sequence analysis of clones.

[Step 4] - The clone from Step 3 is digested with Not I/Bgl II and the 3473 bp fragment is isolated. Construct #4 is digested with Bgl II/Not I and the 4451 bp fragment is isolated. These two fragments are ligated into Not I digested pBlueScript (pBS), resulting the in the transgene disclosed schematically in Figure 7 and via the
5 nucleotide sequence in Figure 8A-C.

EXAMPLE 2

Generation of Transgenic Rats Expressing Human B₁ Bradykinin 1 Receptor

Approximately 20 ug of NSE promoter_CMV intronA_human B1 (Figure 1)
10 cloned into pBluescript was digested with Bam HI. The 4.1 kb insert was separated from the 3 kb vector on a 0.8 % agarose gel. The 4.1 kb band was excised and extracted using Qiaquick Gel Extraction (Qiagen), following extraction the fragment was further purified by separation on a 0.8 % agarose gel. The band was excised and extracted from the gel as before with the modification of twice purifying on the
15 Quiquick columns. The final product was resuspended in 10 mM Tris pH 7.4, 0.1 mM EDTA at a concentration of approximately 50 ng/ul. The CMV (Figure 4) and the Thy-1 promoter constructs (Figure 7) were prepared in a similar manner with the exception that Not I digestion was used to excise the linear DNA fragment for microinjection from the vector.

20 A purified NSE promoter_CMV intronA_human B1 (Construct #1, Figure 1A) fragment was transferred to DNX Transgenic Sciences (Now Xenogen Corporation) in Princeton, NJ under contract for the generation of transgenic rats containing this transgene. Standard methodology is utilized to transfer said construct into Sprague-Dawley rat eggs to create transgenic rat lines (see, e.g., U.S. Patent No. 4,873,191)
25 which have incorporated at least one copy of the transgene into the genome. Three such transgenic lines which were transferred and subjected to further genomic and phenotypic analysis were lines 0004, 0014 and 0015. Line 0004 is estimated to have approximately 10 copies, with 0014 having more than line 0004. Of course, while there is a relationship, copy number and expression level are in general poorly
30 correlated.

A Taqman assay was developed for the transcript resulting from transgenic insert containing the NSE promoter_CMV intronA_human B1 bradykinin receptor coding sequence_BGH poly A signal. The splicing of CMV intronA results in a transcript which includes 118 nucleotides of exon 1 of the neuron specific enolase

gene fused to the human B1 bradykinin receptor coding sequence (Figure 3A). PCR primers were designed such that the 3' end of the forward primers, either NSE_TM1f 5'-GAGTCTGCAGTCCTCGAGAAGC-3' (SEQ ID NO:33) or NSE_TM2f 5'-TGAGTCTGCAGTCCTCGAGAAG-3' (SEQ ID NO:34), corresponded to the
5 spliced transcript and therefore would not detect either unspliced transcript or genomic DNA. Taqman probes, NSE_TAQ1, 5'-CTCCAATCCTCCAACCAGAGCCAGC-3' (SEQ ID NO:35), and NSE_TAQ2, 5'-TCCAATCCTCCAACCAGAGCCAGCT-3' (SEQ ID NO:36) labeled with FAM and TAMRA were designed to detect the PCR products.

10 An Oligotex Direct mRNA kit (Qiagen) was used to prepare mRNA from the brain of 2 transgenic and 1 non-transgenic rat from line 004. Products derived from the transgenic construct were detected using an ABI PRISM 7700 Sequence Detection System with rodent GAPDH utilized as an internal control. Rodent GAPDH was
15 detected in all samples in contrast the product derived from the transgene was only detected in the transgenic animals. This indicates that the transcript derived from the transgenic insert in line 004 is correctly processed and that this assay can be utilized to distinguish transgenic from non-transgenic animals.

Rat genomic DNA was prepared from tissue by proteinase K digestion followed by phenol chloroform extraction and ethanol precipitation. The genomic
20 DNA (5 to 10 ug) was digested with Eco RI and fragments separated on a 1 % agarose gel. DNA was transferred from the gel to Zeta-Probe Genomic Tested blotting membranes (BioRad) using a VacuGene system (Pharmacia Biotech). Pfu polymerase was used to amplify a 701 nucleotide PCR product from the transgenic construct with the forward primer CMV_381F 5'- AATCTCGGGTACGTGTTCCG-3' (SEQ ID NO:37) and reverse primer Enl_gt2r 5'- TTGGCCAGGTAGATTCTGC-3' (SEQ ID NO:38). The product was purified by Qiaquick PCR purification (Qiagen) and radiolabeled with alpha³²PdCTP by random prime labeling (Roche).
25 Hybridization was performed in 0.25 M Na₂HPO₄, 6.5% SDS, and 10% dextran sulfate at 65°C overnight. The blot washed with a final wash of 0.1X SSC 0.1% SDS for 30 minutes at 60°C and exposed to film. There is a single Eco RI site in the NSE promoter construct therefore digestion yields a unit length band of 4132 nucleotides, similarly the CMV promoter construct of 6522 contains a single Eco RI site.
30

EXAMPLE 3

Ligand Binding to Human B₁ Bradykinin Receptor Purified from Transgenic Rats

Three of the five lines (0004, 0014, and 0015) of transgenic rats containing Construct #1 (neuron-specific enolase promoter driving expression of the human B₁ bradykinin receptor), as described in Example Section 2, were tested for the ability to bind ³H-DALK, a compound which is approximately 40 fold selective for this ligand. Also important in these assays is the low expression level of endogenous B₁ receptor in neuronal tissue. Briefly, transgenic animals from line 0004, 0014, and 0015 (all females) were decapitated following anesthesia and the whole brain was removed, bisected sagittally and the entire ½ brain weighed. Weights were as follows: line 0004 (813 mg), line 0014 (851 mg), and 0015 (843 mg). The brain tissue was homogenized with a Polytron in ice cold 50mM Tris·HCl, 1mM EDTA, 1mM o-phenanthroline, pH 7.4. The homogenate was centrifuged at 50,000 x g for 20 minutes. The pellet was resuspended and homogenized a second time in Tris buffer, and the centrifugation step was repeated. The final pellet was resuspended in assay buffer (20 mM HEPES, 120 mM NaCl, 5 mM KCl, 1 mM o-phenanthroline, 0.2uM of enalaprilat (the diacid form and active metabolite of enalapril which is added to inhibit angiotensin converting enzyme), 100 µg/ml bacitracin, 3 µM amastatin, 1 µM phosphoramidon, 0.1% BSA, pH 7.4. The assay was carried out in a 0.5 ml volume at room temperature for sixty minutes with 10 mg wet weight tissue/tube. Total protein was determined using a Bio Rad DC assay kit. Specific binding is measured as that which is sensitive to competition with a B₁ specific ligand, either cold DALK or a compound with specificity for the human B₁ receptor. Figure 9A, 9B and 9C show measurements of the amount of total, nonspecific and specific binding of ³H-DALK to transgenic rat brain tissue which expresses human B₁ bradykinin receptor. Line 0004 (Figure 9A) shows expression of 40 fmol/mg protein, Line 0014 (Figure 9B) shows expression of 4 fmol/mg protein, while Line 0015 (Figure 9C) shows expression of 7 fmol/mg protein. In contrast, no B₁ receptor is detected in the brains of non-transgenic rats. The K_i values determined for three standard lead compounds in Line 0004 are very similar to those obtained at the cloned hB₁ receptor expressed in CHO cells. Therefore, expression of the human B₁ bradykinin receptor in Line 0004 has the properties expected for the human B₁ receptor.

Line 0004 was subjected to autoradiographic study of the expression of human bradykinin B₁ receptor in transgenic rat brain and spinal cord. A transgenic rat (line 0004) was first anesthetized, and then the brain was removed and immediately frozen on dry ice. The coronal sections (20µm) of the brain were prepared in a cryostat. The adjacent sections of selected brain regions were divided into two sets and pre-incubated for 15 minutes at room temperature (RT) in buffer A. Following pre-incubation, two sets of the brain sections were incubated separately in buffer B for 90 min at RT. One set of the sections was incubated with 0.3 nM of [³H]DALK, and another set was incubated with both 0.3 nM of [³H]DALK and 200 µM of unlabeled L-864747. At the end of the incubation period, sections were washed three times (4 min each) in ice-cold buffer A and then rinsed in ice-cold deionized water for five seconds. Sections were dried by cold air at room temperature, then placed in a cassette against Fuji Imaging Plate (BAS-TR2025) at room temperature for a week. The plate was scanned with Fuji BAS-5000 machine, and the images were analyzed using the MCID M5 software (Imaging Research Inc.). Buffer A is 50 mM Tris-HCl, pH 7.5, 120 mM NaCl, 5 mM KCl and Buffer B is 50 mM Tris-HCl, pH 7.5, 120 mM NaCl, 5 mM KCl, 100 µg/ml Bacitracin, Sigma B-0125, 1 µM Phosphoramidon, Sigma R-7385, 1 mM o-Phenanthroline, Sigma P-9375, 3 µM Amastatin, Sigma A-1276, 0.1% BSA (Sigma A-7030). [³H]DALK is purchased from NEN Life Science (Cat.# NET1096).

The purpose of this autoradiographic study is to characterize human bradykinin B₁ receptor expression in the spinal cord and brain tissues of the transgenic rat carrying human bradykinin B₁ receptor gene by autoradiography. The radiotracer, [³H]DALK for the B₁ receptor was employed in the study and an antagonist of human bradykinin B₁ receptor was used to block the receptor specific binding of [³H]DALK. A signal that was not competed by the antagonist was defined as nonspecific binding of [³H]DALK. The results of autoradiographic study demonstrate expression of human bradykinin B₁ receptor in the brain and spinal cord of the transgenic rat. In NSE_human B₁ receptor transgenic line 0004, the expression of human bradykinin B₁ receptor varies among the different regions of the brain and spinal cord examined. The highest binding signals for [³H]DALK in transgenic rats are in the dorsal horn of the spinal cord, the cerebral cortex, hypothalamus, thalamus, cerebellum, substantia nigra, interpeduncular nucleus, nucleus of solitary tract, periaqueductal gray, and pontine nucleus. In contrast, [³H]DALK did not show any

specific binding signal in the corresponding regions of the brain and spinal cord of the non-transgenic rats, showing that integration of the human B₁ bradykinin gene into the rat genome confers a phenotype of non-native, selective binding characteristics to various test compounds and known modulators of the human B₁ bradykinin receptor.

5

EXAMPLE 4

Mapping of the transgene integration site for NSE-hB1 line 0004

Genomic DNA was prepared from tissue of a transgenic rat from line 0004. The genomic DNA was partially digested with restriction endonuclease Sau 3A1 and
10 cloned into the superCOS I vector according to the manufacturer's instructions (Stratagene, La Jolla CA). Cosmid clones were screened by standard in situ hybridization of bacterial colonies using a radiolabeled probe consisting of 701 nucleotides. The probe was obtained using standard PCR conditions with the primers, 5'-AATCTCGGGTACGTGTTCCG 3' (SEQ ID NO:39) and
15 5'-TTGGCCAGGTAGATTCTGC 3' (SEQ ID NO:40), and the NSE-hB1 transgene construct as the template. Positive colonies were re-screened and cosmid DNA was prepared from clones that were positive in the secondary screen. Cosmid end sequencing was performed using T3 and T7 primers. DNA sequence of cosmid clone 19 that was obtained with the T3 primer was found to match rat genomic DNA
20 containing a portion of the pellucidae glycoprotein gene 1 (ZP-1), whereas the sequence from the T7 primer matched a portion of the NSE_hB1 transgene construct. To fine map the transgene integration site, cosmid 19 was digested with the restriction endonuclease DraI, and the resulting fragments were sub-cloned into the vector pBluescript II (Stratagene, La Jolla, CA). Plasmid DNA was prepared from ampicillin
25 resistant colonies and the size of the insert was determined, clones with various size inserts were analyzed by DNA sequence analysis using m13 forward and reverse primers. DNA sequence analysis of clone Dra37 revealed that it contained rat genomic DNA and a portion of the NSE-hB₁ transgene construct. Thus clone Dra37 contained one end of the transgene insertion site. BioInformatic analysis of rat
30 genomic DNA sequence from Dra37 indicated that it matched the DNA sequence of *Rattus norvegicus* clone CH230-6B11 (GenBank Accession number AC097387). The clone CH230-6B11 contains the zona pellucidae glycoprotein gene 1 (ZP1), the same gene that was identified by end sequencing of cosmid clone 19, and is mapped to chromosome 1. Therefore the transgene integrated into chromosome 1 near the ZP1

gene. The delineation of the transgene insertion site permitted the development of a genotyping assay for identification of the line 0004 homozygous transgenic rats. This random integration site contains multiple copies of the transgene. The sequence of clone Dra 37 containing the line 0004 transgene insertion site is as follows:

```

5  GTAGCCTGCC TCCGATATTT GTTAGAACAA CGGTTCCCCG CCACCTACCA ACTGTTTATG
   TTTTCTCTAA CAAAAACCAG ACCGGCCGCT GGGCCTGATA CCTGAGTTCA GTCACCAAGA
   CCCACGTGGC AGAAGGAGAG AACTGACTTC TGCATATTAT CCTCCAACAC ACACACACAC
   ACACACACAC ACACACACAC ACACACACAC ACACACTAAA ATAAATAAAT AGTCTGGGCT
   TGGTGGCACA TTGAGAACTT ACCTCAGAAA AAAGGTAAGT AGATAAAGTA AAATAAAAT
10 GGAGTGAGTC AACTGGAGT TCCATGTTAC CAAATTAAAA CTAGCTTTCT GACCTTCTGA
   GAAACCAGGA CAGAAAGAGG TGAAGGCCAC ATTTTCTAGC CATGCCAACT GCAGCAAACA
   TAACTCTGTT CTGGCTGCCA TTGTCCTTAT GAAAAGTAAG CAGGAGGGAT CTGATCTATT
   AACCAGCTAG CTCTGTGCTT CCCTCCTCTT CTCCCAACCT CCCAAGGAAA ACATACTCCG
   TCCTTTTCCT TTGTTTTATT CTGCTTCCT GTCTAGGAAA TCACTCCCCT CCAAGGCGTC
15 AGAACACATT CTGGCTTACA GAATGAAGTT TTACCCAATT CTAGAATCAC AAAATATAGC
   CAACGTAAAC CTTGAATGTG ATCTAATTGG TCTAAGAGGC AGAAATGAGA TGAAGAAAAA
   AACTGCCGAC ATAGATTTCA GTCTATGGGA TGATGGGCAC ATAAACAATA AGAAGAAAGT
   GCCAGACAGG GGTAGGTGCT CTAAATACAA GATAAATTAG AGCAGGTGTA GAAGATGGTA
   CTGGGGATTG GAGGGGCGAC TGCTTTAGGC AGGGTATGGG AAAGGTATGC CCCCTGAGAG
20 AGGATGTTCA TTTTTCAGC TTGAATTTTA TTTTAGTGTA TGTGTATGCA TGTGCCACAG
   CAAATGTATA GAAGTAAAAG GAGACCTTGA GAGAAGTGGT TCACTCCTCC CATGTTGGTC
   TTGGGATCGA AGTCAGGTTG TTAGACTTGA CAGGAAGTTT CTCTCCCCAG TGAGCTGTCT
   CACCAGCCCA AAGGGTGGCA ACATTTTTGC TGAGACCTAA ATAAAGGACA TGCCTCAGTT
   CAGAAACCAC AGATATCTGA TCAACCAAGC TCCTGCAGTC TCACCTCATC TTCCTCTCAG
25 CCACACTGGC CCTTCAGTGG CCCCAGCAGT CCCCAGGTA GGTGGCTCAA AATGTTTATG
   TGGCTACCTT TCATCAACTC CTTCCCCATC TCCAGCCCCG GCCAGACCCT CCAGGGCAAA
   CTGAGGCCTC ATCTGAGCTC CTCTCTGCT CGCCCAATCC TTCCAACCCC CTATGGTGGT
   ATTGTCTGTT TACCCTATAG GACATCCTAT AGGGTAAACA GACAATAGAC CATAGGACAA
   CAGGCAGGAG CATGCCTGCT ATTGTCCTCC CTTGTCCTCC CTGCCATCCT AAAGCTGGCA
30 GGTGGCTGGT GGTATATGGA GGATGTAGCT GGGCCAGGGA AAAGATCCTG CACTAAAAAT
   CTGAAGCTAA AAATAACAGG ACACGGGATG GAGGAGCTCA GGTGGTATGG CTGACACAGA
   AAATGTCTGC TCCTGTATGG GACATTTGCC CCTCTTCTCC AAATATAAGA CAGGATGAGG
   CCTAGCTTTT GCTGCTCCAA AGTTTTA (SEQ ID NO:41).

```

EXAMPLE 5

Development of a Genotype Assay for NSE_hB₁ line 0004

Homozygous Transgenic Rats

The genomic DNA sequence upstream of the transgene insertion site was
5 utilized to design forward, 5'-GAGGTGAAGGCCACATTTTCTAGC -3' (SEQ ID
NO:42), and reverse 5'- ATGGGGAAGGAGTTGATGAAAGGTAGCC -3' (SEQ ID
NO:43), PCR primers. Using the cosmid DNA template and standard PCR
procedures these primers generate a product of 922 nucleotides. This fragment of 922
nucleotides serves as an external probe that can be radiolabeled and used in Southern
10 blot analysis to discern wild type from transgenic chromosomes. Accordingly,
Southern blot analysis of wild type rat genomic DNA with the restriction
endonuclease DraI results in the detection of a single fragment of approximately 3.1
kb with the external probe. In contrast, the digestion of genomic DNA prepared from
a rat heterozygous for the transgene results in the detection of two fragments, one of
15 3.1kb and a second of approximately 1.6kb. The 1.6 kb fragment corresponds to the
chromosome with the transgene insertion site, whereas the 3.1 kb fragment
corresponds to the wild type chromosome. Thus, DraI digestion and Southern blot
analysis with the external probe can be used to identify homozygous wild type
animals, heterozygous and homozygous transgenics. This was used to identify and
20 establish a homozygous transgenic breeding colony. Significantly, the line 0004
homozygous animals express 2-fold more human B₁ bradykinin receptor in the brain
and spinal cord than the heterozygous animals.

EXAMPLE 6

25 Ex vivo Receptor Occupancy Assay in NSE_hB₁ transgenic rat

Transgenic rats of either sex are placed in an induction chamber and
anesthetized with isoflurane under a Flow Sciences hood. Once anesthetized, the rat
is placed on a circulating water warming blanket (Gaymar T-pump) and anesthesia is
maintained using 2% isoflurane by means of a nose cone. The tail vein is cannulated
30 with a 25G winged infusion set-up connected to a syringe containing either test
compound or vehicle. The desired dose of test compound is administered. At the
experimental end-point a blood sample is taken, the rat is euthanized, and tissue is
removed (typically brain and spinal cord) for subsequent assays.

For autoradiographic analysis of human B₁ receptor expression, tissues removed from transgenic rats were frozen on dry ice powder, and stored at -70°C. Coronal sections of the brain and the transverse sections of the spinal cord were prepared with cryostat (Leica, CM3050) at 20 µM of each. The frozen sections were stored at -70°C. For analysis, frozen sections were warmed at room temperature (RT) for 15 minutes, then followed by 15 minutes preincubation in the buffer without radioligand at RT. After preincubation, the sections were transferred to the incubation buffer, and incubated for 90 minutes at RT. Total binding, both non-specific and specific, was determined by incubating in buffer containing 0.3 nM [H-3] DALK. An adjacent section was utilized to determine non-specific binding, which was incubated in buffer containing 0.3 nM [H-3] DALK and 200 nM of a non-peptide receptor antagonist that exhibits high affinity and specificity for the human B₁ bradykinin receptor. Following the 90 minute incubation, the sections were washed three times, 3 minutes each, in buffer, rinsed in DIH₂O for 30 seconds at 4°C, and then dried by air blower at RT. The sections were placed against Fuji imaging plates, and exposed for a week at RT. The plates were scanned with Fuji PhosphorImager BAS 5000, and the images were analyzed with MCID M5 software. Figure 10 shows autoradiograms of brain and spinal cord sections from NSE_hB₁ line 0004 transgenic rats. Regions of the brain and spinal cord that exhibit high levels of binding are indicated. Specific [H-3] DALK binding (total binding – nonspecific binding) is indicative of the level of human B₁ bradykinin receptor expression. There is no detectable specific binding of [H-3] DALK in non-transgenic control rats.

For homogenate-based binding assay, thirty-five milligrams of frozen brain (cerebral cortex or cerebellum) or spinal cord is homogenized with a Polytron, in a large volume of ice-cold assay buffer (20mM HEPES, 120mM NaCl, 5mM KCl, pH 7.4) and transferred to two chilled centrifuge tubes. To pellet membranes the tubes are centrifuged for 10 minutes at 75,000xg in a rotor pre-cooled to 4°C. The supernatant is discarded and each tube is rinsed with 20ml ice-cold buffer and then homogenized pellets above in ice-cold assay buffer. The homogenate is pooled and added to a tube containing the radiotracer, 20pM of a non-peptide human B₁ receptor antagonist that is labeled with ³⁵S, in each tube containing 0.5ml room temperature assay buffer. Nonspecific binding is determined by adding homogenate to tubes containing the radiotracer and 100nM of the unlabeled non-peptide human B₁ receptor antagonist. At set time points (1,2,4,6,8,10 minutes) the contents of three tubes are

filtered over individual 25mm GF/B filters presoaked in 0.05% Triton X-100. The filtration step is performed by adding 4ml ice-cold assay buffer to each of the three replicate tubes, pouring the contents over the filters, and washing each filter two times with 4ml ice-cold buffer. A Hoeffler FH 225V filtration manifold is used for the
5 filtration. The nonspecific binding tubes are similarly filtered after finishing the 6 time points. Filters are transferred to 5ml scintillation vials and counted after soaking 10 hours in 3ml Beckman Ready Safe scintillation fluid.

The specific binding is calculated at each time point (total cpm – nonspecific cpm) and the slope of the association is determined by linear regression. Receptor
10 occupancy in a drug treated animal is determined by the following equation:

$$\% \text{ Occupancy} = (1 - (\text{slope}_{\text{drug}} / \text{slope}_{\text{vehicle}})) \times 100$$

$\text{slope}_{\text{drug}}$ is the slope of the association rate line from a drug treated animal.

$\text{slope}_{\text{vehicle}}$ is the slope determined for a vehicle treated animal.

Various patent and journal publications are cited herein, the disclosures of
15 which are all incorporated by reference in their entireties.

WHAT IS CLAIMED IS:

1. A non-human transgenic animal having incorporated into its genome at least one copy of a transgene encoding a primate bradykinin B₁ receptor gene, or a functional equivalent thereof, such that the transgenic animal demonstrates a humanized B₁ bradykinin receptor occupancy or binding profile.
2. A non-human transgenic animal of claim 1 wherein the non-human transgenic animal is selected from the group consisting of rats, mice, cows, pigs, rabbits, guinea pigs, sheep, hamsters, and goats.
3. A non-human transgenic animal of claim 2 wherein the non-human transgenic animal is further selected from the group consisting of rats and mice.
4. A non-human transgenic animal of claim 1 wherein said transgene is operatively linked to a heterologous promoter which effects expression of a primate bradykinin B₁ receptor gene.
5. A non-human transgenic animal of claim 4 wherein the non-human transgenic animal is selected from the group consisting of rats, mice, cows, pigs, rabbits, guinea pigs, sheep, hamsters, and goats.
6. A non-human transgenic animal of claim 5 wherein the non-human transgenic animal is further selected from the group consisting of rats and mice.
7. A non-human transgenic animal of claim 4 wherein said heterologous promoter is the rat neuronal specific enolase (NSE) promoter or the cytomegalovirus (CMV) promoter.
8. A transgenic rat having incorporated into its genome at least one copy of a transgene encoding a primate bradykinin B₁ receptor gene, or a functional equivalent thereof, such that the transgenic animal demonstrates a humanized B₁ bradykinin receptor occupancy or binding profile.

9. A transgenic rat of claim 8 wherein said transgene is expressed from a heterologous promoter.

5 10. A non-human transgenic animal of claim 9 wherein said heterologous promoter is the rat neuronal specific enolase (NSE) promoter or the cytomegalovirus (CMV) promoter.

10 11. A transgenic rat of claim 10 wherein the transgene is a discistronic transgene which further comprises a reporter gene expressed at detectable levels within the transgenic rat.

12. A transgenic rat of claim 11 wherein said transgene is expressed from a heterologous promoter.

15

13. A non-human transgenic animal of claim 12 wherein said heterologous promoter is the rat neuron specific enolase (NSE) promoter or the cytomegalovirus (CMV) promoter.

20 14. A transgenic rat having incorporated into its genome at least one copy of a transgene encoding a human bradykinin B₁ receptor gene, or a functional equivalent thereof, such that the transgenic animal demonstrates a humanized B₁ bradykinin receptor occupancy or binding profile.

25 15. A transgenic rat of claim 14 wherein said transgene is expressed from a heterologous promoter.

30 16. A transgenic rat of claim 15 wherein said heterologous promoter is the rat neuronal specific enolase (NSE) promoter or the cytomegalovirus (CMV) promoter.

17. A transgenic rat of claim 16 wherein the transgene is NSE_CMV intronA_hB1 cds_BGH poly A.

18. A transgenic rat of claim 16 wherein the transgene is CMV_CMVintronA_hB1cds_IRES2_LacZ_BGH polyA.

5 19. A transgenic rat of claim 16 wherein the transgene is Thy1_hB1cds_IRES2_LacZ_BGHpolyA.

20. An ex vivo method of determining receptor occupancy of a primate bradykinin receptor protein and a test compound, which comprises:

- 10 a) administering the test compound to a non-human transgenic animal, wherein the transgenic animal contains at least one stably integrated copy of a non-native primate B₁ bradykinin gene which expresses levels of non-native primate B₁ bradykinin receptor at levels substantially greater than expression of any endogenous, native B1 bradykinin gene within a target transgenic animal tissue;
- 15 b) removing a tissue sample from the transgenic animal of step a);
- c) determining total binding, specific binding and non-specific binding of the test compound to the primate B₁ bradykinin receptor by analysis of the tissue sample of step c);
- 20 d) calculating receptor occupancy of the test compound within the transgenic animal of step a).

21. A method of claim 20 wherein the total binding, specific binding and non-specific binding determination of step c) is accomplished by autoradiography or a tissue homogenate-based binding assay.

25

22. The method of claim 21 wherein the non-native primate B₁ bradykinin gene is a human B₁ bradykinin gene.

23. The method of claim 22 wherein the non-native primate B₁ bradykinin gene is operatively linked to a heterologous promoter.

30

24. The method of claim 23 wherein said heterologous promoter is the rat neuronal specific enolase (NSE) promoter or the cytomegalovirus (CMV) promoter.

25. The method of claim 21 wherein the non-human transgenic animal is selected from the group consisting of rats and mice.

5 26. The method of claim 25 wherein the non-human transgenic animal is a transgenic rat.

27. The method of claim 21 wherein the non-native primate B₁ bradykinin gene is operatively linked to a heterologous promoter and further comprises a
10 non-human transgenic animal selected from the group consisting of rats and mice.

28. The method of claim 27 wherein the non-human transgenic animal is a transgenic rat.

15

1/16




FIGURE 1

>NSE_CMV intronA_hB1 cds_BGH poly A sequence

```

GGATCCTGAG CTCCTCCTCT GCTCGCCCAA TCCTTCCAAC CCCCTATGGT GGTATGGCTG
ACACAGAAAA TGTCTGCTCC TGTATGGGAC ATTTGCCCTT CTTCTCCAAA TATAAGACAG
GATGAGGCCT AGCTTTTGCT GCTCCAAAGT TTTAAAAGAA CACATTGCAC GGCATTTAGG
GACTCTAAAG GGTGGAGGAG GAATGAGGGA ATTGCATCAT GCCAAGGCTG GTCCTCATCC
ATCACTGCTT CCAGGGCCCA GAGTGGCTTC CAGGAAGTAT TCTTACAAAG GAAGCCCGAT
CTGTAGCTAA CACTCAGAGC CCATTTTCCT GCGTTAACCC CTCCCGACCT CATATACAGG
AGTAACATGA TCAGTGACCT GGGGGAGCTG GCCAAACTGC GGGACCTGCC CAAGCTGAGG
GCCTTGGTGC TGCTGGACAA CCCCTGTGCC GATGAGACTG ACTACCGCCA GGAGGCCCTG
GTGCAGATGG CACACCTAGA GCGCCTAGAC AAAGAGTACT ATGAGGACGA GGACCGGGCA
GAAGCTGAGG AGATCCGACA GAGGCTGAAG GAGGAACAGG AGCAAGAACT CGACCCGGAC
CAAGACATGG AACCCTACCT CCCGCCAAGT TAGTGGCTCC TCTAGCCTGC AGGGACAGTA
AAGGTGATGG CAGGAAGGCA GTCCCCGGAG GTCAAAGGCT GGGCAGCGCG GAGGAGAGGC
CAGAGTCAGA GGCTGCGGGT ATCTCAGATA TGAAGGAAAG ATGAGAGAGG CTCAGGAAGA
GGTAAGAAAA GACACAAGAG ACCAGAGAAG GGAGAAGAAT TAGAGAGGGA GGCAGAGGAC
CGCTGTCTCT ACAGACATAG CTGGTAGAGA CTGGGAGGAA GGGATGAACC CTGAGCGCAT
GAAGGGAAGG AGGTGGCTGG TGGTATATGG AGGATGTAGC TGGGCCAGGG AAAAGATCCT
GCACTAAAAA TCTGAAGCTA AAAATAACAG GACACGGGGT GGAGAGGCGA AAGGAGGGCA
GAGTGAGGCA GAGAGACTGA GAGGCTGGG GATGTGGGCA TTCCGGTAGG GCACACAGTT
CACTTGCTCT CTCTTTTTTC AGGAGGCCAA AGATGCTGAC GTCAAGAACT CATAATACCC
CAGTGGGGAC CACCGCATTC ATAGCCCTGT TACAAGAAGT GGGAGATGTT CTTTTTTGTC
CCAGACTGGA AATCCGTTAC ATCCCGAGGC TCAGGTTCTG TGGTGGTCAT CTCTGTGTGG
CTTGTTCTGT GGGCCTACCT AAAGTCCTAA GCACAGCTCT CAAGCAGATC CGAGGCGACT
AAGATGCTAG TAGGGGTGT CTGGAGAGAA GAGCCGAGGA GGTGGGCTGT GATGGATCAG
TTCAGCTTTC AAATAAAAAG GCGTTTTTAT ATTCTGTGTC GAGTTCGTGA ACCCTGTGG
TGGGCTTCTC CATCTGTCTG GGTAGTACC TGCCACTATA CTGGAATAAG GGGAGCCCTG
CTTCCCTCGA GTTGGCTGGA CAAGGTTATG AGCATCCGTG TACTTATGGG GTTGCCAGCT
TGGTCCTGGA TCGCCCGGGC CCTTCCCCCA CCCGTTGCGT TCCCCACCAC CACCCGCGCT
CGTACGTGCG TCTCCGCTG CAGCTCTTGA CTCATCGGGG CCCCCGGGTC ACATGCGCTC
GCTCGGCTCT ATAGGCGCCG CCCCCTGCCC ACCCCCCGCC CGCGCTGGGA GCCGCAGCCG
CCGCCACTCC TGCTCTCTCT GCGCCGCCGC CGTCACCACC GCCACCGCCA CCGGCTGAGT
CTGCAGTCCT CGAGGTAAGT ACCGCCTATA GACTCTATAG GCACACCCCT TTGGCTCTTA
TGCATGCTAT ACTGTTTTTG GCTTGGGGCC TATACACCCC CGCTTCCTTA TGCTATAGGT
GATGGTATAG CTTAGCCTAT AGGTGTGGGT TATTGACCAT TATTGACCAC TCCCCTATTG
GTGACGATAC TTTCCATTAC TAATCCATAA CATGGCTCTT TGCCACAACAT ATCTCTATTG
GCTATATGCC AATACTCTGT CTTTCAGAGA CTGACACGGA CTCTGTATTT TTACAGGATG
GGGTCCCATT TATTATTTAC AAATTCACAT ATACAACAAC GCCGTCCCCC GTGCCCAGAG
TTTTTATTAA ACATAGCGTG GGATCTCCAC GCGAATCTCG GGTACGTGTT CCGGACATGG
GCTCTTCTCC GGTAGCGGCG GAGCTTCCAC ATCCGAGCCC TGGTCCCATG CCTCCAGCGG
CTCATGGTCG CTCGGCAGCT CTTTGCTCCT AACAGTGGAG GCCAGACTTA GGCACAGCAC
AATGCCACCC ACCACAGTG TGCCGCACAA GGCCGTGGCG GTAGGGTATG TGTCTGAAAA
TGAGCGTGGA GATTGGGCTC GCACGGCTGA CGCAGATGGA AGACTTAAGG CAGCGGCAGA
AGAAGATGCA GGCAGCTGAG TTGTTGTATT CTGATAAGAG TCAGAGGTAA CTCCCGTTGC

```

FIGURE 2A

3/16

```
GGTGCTGTTA ACGGTGGAGG GCAGTGTAGT CTGAGCAGTA CTCGTTGCTG CCGCGCGCGC
CACCAGACAT AATAGCTGAC AGACTAACAG ACTGTTTCCTT TCCATGGGTC TTTTCTGCAG
AAGCTTGGTA CCGCCGCCAC CATGGCATCA TCCTGGCCCC CTCTAGAGCT CCAATCCTCC
AACCAGAGCC AGCTCTTCCC TCAAAATGCT ACGGCCTGTG ACAATGCTCC AGAAGCCTGG
GACCTGCTGC ACAGAGTGCT GCCGACATTT ATCATCTCCA TCTGTTTCTT CGGCCTCCTA
GGGAACCTTT TTGTCTTGTT GGTCTTCCTC CTGCCCCGGC GGCAACTGAA CGTGGCAGAA
ATCTACCTGG CCAACCTGGC AGCCTCTGAT CTGGTGTTTG TCTTGGGCTT GCCCTTCTGG
GCAGAGAATA TCTGGAACCA GTTTAACTGG CCTTTCGGAG CCCTCCTCTG CCGTGTCTATC
AACGGGGTCA TCAAGGCCAA TTTGTTTCATC AGCATCTTCC TGGTGGTGGC CATCAGCCAG
GACCGCTACC GCGTGCTGGT GCACCCATAG GCCAGCCGGA GGCAGCAGCG GCGGAGGCAG
GCCCCGGTCA CCTGCGTGCT CATCTGGGTT GTGGGGGGCC TCTTGAGCAT CCCCACATTC
CTGCTGCGAT CCATCCAAGC CGTCCCAGAT CTGAACATCA CCGCCTGCAT CCTGCCTCCTC
CCCCATGAGG CCTGGCACTT TGCAAGGATT GTGGAGTTAA ATATTCTGGG TTTCTCCTA
CCACTGGCTG CGATCGTCTT CTTCAACTAC CACATCCTGG CCTCCCTGCG AACGCGGGAG
GAGGTCAGCA GGACAAGGTG CGGGGGCCGC AAGGATAGCA AGACCACAGC GCTGATCCTC
ACGCTCGTGG TTGCCTTCCT GGTCTGCTGG GCCCCTTACC ACTTCTTTGC CTTCTGGA
TTCTTATTCC AGGTGCAAGC AGTCCGAGGC TGCTTTTGGG AGGACTTCAT TGACCTGGGC
CTGCAATTGG CCAACTTCTT TGCCTTCACT AACAGCTCCC TGAATCCAGT AATTTATGTC
TTTGTGGGCC GGCTCTTCAG GACCAAGGTC TGGGAACTTT ATAAACAATG CACCCTAAA
AGTCTTGCTC CAATATCTTC ATCCCATAGG AAAGAAATCT TCCAACTTTT CTGGCGGAAT
TAAAACAGCA TTGAACCAAG AAGCTTGGCT TTCTTATCAA TTCTTTGTGA CATAATAAAT
GCTATTGTGA TAGGCTAAAT GATTACTCCC GTAGATTGGG GGGTACCTAA TCCCTGGACT
TGATGAGCGG CCTCGAGCAT GCATCTAGAG GGCCCTATTC TATAGTGTCA CCTAAATGCT
AGAGCTCGCT GATCAGCCTC GACTGTGCCT TCTAGTTGCC AGCCATCTGT TGTTTGCCCC
TCCCCCGTGC CTTCTTGAC CCTGGAAGGT GCCACTCCCA CTGTCCTTTC CTAATAAAAT
GAGGAAATTG CATCGCATTG TCTGAGTAGG TGTCATTCTA TTCTGGGGGG TGGGGTGGGG
CAGGACAGCA AGGGGGAGGA TTGGGAAGAC AATAGCAGGC ATGCTGGGAT CC (SEQ ID
NO:1)
```

FIGURE 2B

4/16




FIGURE 3A


5/16

>NSE_hB1_transcript

```
GCCGCCCCCT GCCCACCCTC CGCCCGCGCT GGGAGCCGCA GCCGCCGCCA CTCCTGCTCT
CTCTGCGCCG CCGCCGTCAC CACCGCCACC GCCACCGGCT GAGTCTGCAG TCCTCGAGAA
GCTTGGTACC GCCGCCACCA TGGCATCATC CTGGCCCCCT CTAGAGCTCC AATCCTCCAA
CCAGAGCCAG CTCCTCCCTC AAAATGCTAC GGCCTGTGAC AATGCTCCAG AAGCCTGGGA
CCTGCTGCAC AGAGTGTGTC CGACATTTAT CATCTCCATC TGTTTCTTCG GCCTCCTAGG
GAACCTTTTT GTCTGTGTTG TCTTCCTCCT GCCCCGGCGG CAACTGAACG TGGCAGAAAT
CTACCTGGCC AACCTGGCAG CCTCTGATCT GGTGTTTGTC TTGGGCTTGC CCTTCTGGGC
AGAGAATATC TGAACCCAGT TTAACCTGGC TTTCGGAGCC CTCCTCTGCC GTGTCATCAA
CGGGGTATC AAGGCCAATT TGTTTCATCAG CATCTTCCTG GTGGTGGCCA TCAGCCAGGA
CCGCTACCGC GTGCTGGTGC ACCCTATGGC CAGCCGGAGG CAGCAGCGGC GGAGGCAGGC
CCGGGTCACT TGCCTGCTCA TCTGGGTGTT GGGGGGCCCTC TTGAGCATCC CCACATTCTT
GCTGCGATCC ATCCAAGCCG TCCCAGATCT GAACATCACC GCCTGCATCC TGCTCCTCCC
CCATGAGGCC TGGCACTTTG CAAGGATTGT GGAGTTAAAT ATTCTGGGTT TCCTCCTACC
ACTGGCTGCG ATCGTCTTCT TCAACTACCA CATCCTGGCC TCCCTGCGAA CGCGGGAGGA
GGTCAGCAGG ACAAGGTGCG GGGGCCGCAA GGATAGCAAG ACCACAGCGC TGATCCTCAC
GCTCGTGGTT GCCTTCCTGG TCTGCTGGGC CCCTTACCAC TTCTTTGCCT TCCTGGAATT
CTTATTCCAG GTGCAAGCAG TCCGAGGCTG CTTTGGGAG GACTTCATTG ACCTGGGCCT
GCAATTGGCC AACTTCTTTG CCTTCACTAA CAGCTCCCTG AATCCAGTAA TTTATGTCTT
TGTGGGCCGG CTCTTCAGGA CCAAGGTCTG GGAACTTTAT AAACAATGCA CCCCTAAAAG
TCTTGCTCCA ATATCTTCAT CCCATAGGAA AGAAATCTTC CAACTTTTCT GGCGGAATTA
AAACAGCATT GAACCAAGAA GCTTGGCTTT CTTATCAATT CTTTGTGACA TAATAAATGC
TATTGTGATA GGCTAAATGA TTAATCCCGT AGATTGGGGG GTACCTAATC CCTGGACTTG
ATGACGCTCG AGCATGCATC TAGAGGGCCC TATTCTATAG TGTCACCTAA ATGCTAGAGC
TCGCTGATCA GCCTCGACTG TGCCTTCTAG TTGCCAGCCA TCTGTTGTTT GGGCCTCCCC
CGTGCCTTCC TTGACCTTGG AAGGTGCCAC TCCCCTGTC CTTTCCTAAT AAAATGAGGA
AATTGCATCG CATTGTCTGA GTAGGTGTCA TTCTATTCTG GGGGGTGGGG TGGGGCAGGA
CAGCAAGGGG GAGGATTGGG AAGACAATAG CAGGCATGCT GGGGA (SEQ ID NO:2)
```

FIGURE 3B

6/16



CMV Promoter – CMV Intron A-human B1 cds-BGH

2986 bp

FIGURE 4

7/16




FIGURE 5

8/16

>promoterCMV_CMVintronA_hB1cds_IRES2_LacZ_BGH polyA

```

GGCCGCCGAT GTACGGGCCA GATATACGCG TTGACATTGA TTATTGACTA GTTATTAATA
GTAATCAATT ACGGGGTCAT TAGTTCATAG CCCATATATG GAGTTCCGCG TTACATAACT
TACGGTAAAT GGCCCGCCTG GCTGACCGCC CAACGACCCC CGCCCATTTGA CGTCAATAAT
GACGTATGTT CCCATAGTAA CGCCAATAGG GACTTTCCAT TGACGTCAAT GGGTGGAGTA
TTTACGGTAA ACTGCCCCTG TGGCAGTACA TCAAGTGTAT CATATGCCAA GTACGCCCCC
TATTGACGTC AATGACGGTA AATGGCCCGC CTGGCATTAT GCCCAGTACA TGACCTTATG
GGACTTTCCT ACTTGGCAGT ACATCTACGT ATTAGTCATC GCTATTACCA TGGTGATGCG
GTTTTGGCAG TACATCAATG GCGGTGGATA GCGGTTTGAC TCACGGGGAT TTCCAAGTCT
CCACCCCATT GACGTCAATG GGAGTTTGTT TTGGCACCAA AATCAACGGG ACTTTCCAAA
ATGTCGTAAC AACTCCGCCC CATTGACGCA AATGGGCGGT AGGCGTGTAC GGTGGGAGGT
CTATATAAGC AGAGCTCTCT GGCTAACTAG AGAACCCACT GCTTACTGGC TTATCGAAAT
TAATACGACT CACTATAGGT AAGTACCGCC TATAGACTCT ATAGGCACAC CCTTTGGCT
CTTATGCTATG CTATACGTGT TTTGGCTTGG GGCCTATACA CCCCCTTCTT CCCTTTGGCT
AGGTGATGGT ATAGCTTAGC CTATAGGTGT GGGTTATTGA CCATTATTGA CCACTCCCTT
ATTGGTGACG ATACTTTCCA TTAATAATCC ATAACATGGC TCTTTGCCAC AACTATCTCT
ATTGGCTATA TGCCAATACT CTGTCTTCA GAGACTGACA CGGACTCTGT ATTTTACAG
GATGGGGTCC CATTTATTAT TTACAAATTC ACATATACAA CAACGCCGTC CCCCCTGCC
GCAGTTTTTA TTAAACATAG CGTGGGATCT CCACGCGAAT CTCGGGTACG TGTTCCGGAC
ATGGGCTCTT CTCCGGTAGC GGCGGAGCTT CCACATCCGA GCCCTGGTCC CATGCCTCCA
GCGGCTCATG GTCGCTCGGC AGCTCCTTGC TCCTAACAGT GGAGGCCAGA CTTAGGCACA
GCACAATGCC CACCACCACC AGTGTGCCGC ACAAGGCCGT GCGGGTAGGG TATGTGTCTG
AAAATGAGCG TGGAGATTGG GCTCGCACGG CTGACGCAGA TGAAGACTT AAGGCAGCGG
CAGAAGAAGA TGCAGGCAGC TGAGTTGTTG TATTCTGATA AGAGTCAGAG GTAACCTCCG
TTGCGGTGCT GTTAACGGTG GAGGGCAGTG TAGTCTGAGC AGTACTCGTT GCTGCCCGCG
GCGCCACCAG ACATAATAGC TGACAGACTA ACAGACTGTT CCTTTCCATG GGTCTTTTCT
GCAGAAGCTT GGTACCGCCG CCACCATGGC ATCATCCTGG CCCCCTCTAG AGTCTCAATC
CTCCAACCAG AGCCAGCTCT TCCCTCAAAA TGCTACGGCC TGTGACAATG CTCCAGAAGC
CTGGGACCTG CTGCACAGAG TGCTGCCGAC ATTTATCATC TCCATCTGTT TCTTCGGCCT
CCTAGGGAAC CTTTTTGTCC TGTTGGTCTT CCTCTGCCC CGGCGGCAAC TGAACGTGGC
AGAAATCTAC CTGGCCAACC TGGCAGCCTC TGATCTGGTG TTTGTCTTGG GCTTGCCCTT
CTGGGCAGAG AATATCTGGA ACCAGTTTAA CTGGCCTTTC GGAGCCCTCC TCTGCCGTGT
CATCAACGGG GTCATCAAGG CCAATTGTGT CATCAGCATC TTCCTGGTGG TGGCCATCAG
CCAGGACCGC TACCGCGTGC TGGTGACCCC TATGGCCAGC CGGAGGCAGC AGCGGCGGAG
GCAGGCCCGG GTCACCTGCG TGCTCATCTG GGTGTGGGG GGCCTCTTGA GCATCCCCAC
ATTCTGTCTG CGATCCATCC AAGCCGTCCC AGATCTGAAC ATCACCGCCT GCATCCTGCT
CCTCCCCCAT GAGGCCTGGC ACTTTGCAAG GATTGTGGAG TTAAATATTC TGGGTTTCCT
CCTACCACTG GCTGCGATCG TCTTCTTCAA CTACCACATC CTGGCCTCCC TGCGAACGCG
GGAGGAGGTC AGCAGGACAA GGTGCGGGGG CCGCAAGGAT AGCAAGACCA CAGCGCTGAT
CCTCACGCTC GTGGTTGCC TCTGTGCTCG CTGGGCCCC TACCACTTCT TTGCCTTCCT
GGAATTCTTA TTCCAGGTGC AAGCAGTCCG AGGCTGCTTT TGGGAGGACT TCATTGACCT
GGGCCTGCAA TTGGCCAAC TCTTTGCCCT CACTAACAGC TCCCTGAATC CAGTAATTTA
TGTCTTTGTG GGCCGGCTCT TCAGGACCAA GGTCTGGGAA CTTTATAAAC AATGCACCCC
TAAAAGTCTT GCTCCAATAT CTTTATCCCA TAGGAAAGAA ATCTTCCAAC TTTTCTGGCG
GAATTAATGC AGTCGACGGT ACCGCGGGCC CGGGATCCGC CCCTCTCCCT CCCCCCCCC
TAACGTTACT GGCCGAAGCC GCTTGAATA AGGCCGGTGT GCGTTTGTCT ATATGTTATT
TTCCACCATA TTGCCGTCTT TTGGCAATGT GAGGGCCCGG AAACCTGGCC CTGTCTTCTT
GACGAGCATT CCTAGGGGTC TTTCCCTCT CGCCAAAGGA ATGCAAGGTC TGTTGAATGT
CGTGAAGGAA GCAGTTCCTC TGGAAGCTTC TTGAAGACAA ACAACGTCTG TAGCGACCTT
TTGCAGGCAG CGGAACCCCC CACCTGGCGA CAGGTGCCTC TGCGGCCAAA AGCCACGTGT
ATAAGATACA CCTGCAAAG CGGCACAACC CCAGTGCCAC GTTGTGAGTT GGATAGTTGT
GGAAAGAGTC AAATGGCTCT CCTCAAGCGT ATCAACAAG GGGCTGAAGG ATGCCAGAA
GGTACCCCAT TGTATGGGAT CTGATCTGGG GCCTCGGTAC ACATGCTTTA CATTGTTTAA
GTGAGGTTTA AAAAAACGTC TAGGCCCCC GAACACGGG GACGTGGTTT TCCTTTGAAA
AACACGATGA TAATATGGCC ACAACCATGA TAGATCCCGT CGTTTTACAA CGTCGTGACT
GGGAAAACCC TGGCGTTACC CAACTTAATC GCCTTGACAG ACATCCCCCT TTCGCCAGCT
GGCGTAATAG CGAAGAGGCC CGCACCGATC GCCCTTCCCA ACAGTTGCGC AGCCTGAATG

```

FIGURE 6A

GCGAATGGCG CTTTGCCCTGG TTTCCGGCAC CAGAAGCGGT GCCGGAAGC TGGCTGGAGT
 GCGATCTTCC TGAGGCCGAT ACTGTCTGTC TCCCTCAAA CTGGCAGATG CACGGTTACG
 ATGCGCCCAT CTACACCAAC GTGACCTATC CCATTACGGT CAATCCGCCG TTTGTTCCCA
 CGGAGAATCC GACGGGTGTG TACTCGCTCA CCTTTAATGT TGATGAAAGC TGGCTACAGG
 AAGGCCAGAC GCGAATTATT TTTGATGGCG TTAACTCGGC GTTTCATCTG TGGTGCAACG
 GCGCTGGGT CGGTTACGGC CAGGACAGTC GTTTGCCGTC TGAATTTGAC CTGAGCGCAT
 TTTTACGCGC CGGAGAAAAC CGCTCGCGG TGATGGTGCT GCGCTGGAGT GACGGCAGTT
 ATCTGGAAGA TCAGGATATG TGGCGGATGA GCGGCATTTT CCGTGACGTC TCGTTGCTGC
 ATAAACCGAC TACACAAATC AGCGATTTCC ATGTTGCCAC TCGCTTTAAT GATGATTTCA
 GCCGCGCTGT ACTGGAGGCT GAAGTTCAGA TGTGCGGCGA GTTGCGTGAC TACCTACGGG
 TAACAGTTTC TTTATGGCAG GGTGAAACGC AGGTCGCCAG CGGCACCGCG CCTTTCGGCG
 GTGAAATTAT CGATGAGCGT GGTGGTTATG CCGATCGCGT CACACTACGT CTGAACGTCG
 AAAACCCGAA ACTGTGGAGC GCCGAAATCC CGAATCTCTA TCGTGCGGTG GTTGAACGTC
 ACACCGCCGA CGGCACGCTG ATTGAAGCAG AAGCCTGCGA TGTGCGTTTC CGCGAGGTGC
 GGATTGAAAA TGGTCTGCTG CTGCTGAACG GCAAGCCGTT GCTGATTGCA GCGCTTAACC
 GTCACGAGCA TCATCCTCTG CATGGTCAGG TCATGGATGA GCAGACGATG GTGCAGGATA
 TCCTGCTGAT GAAGCAGAAC AACTTTAACG CCGTGCGCTG TTCGCATTAT CCGAACCATC
 CGCTGTGGTA CACGCTGTGC GACCGCTACG GCCTGTATGT GGTGGATGAA GCCAATATTG
 AAACCCACGG CATGGTGCCA ATGAATCGTC TGACCGATGA TCCGCGCTGG CTACCGGCCGA
 TGAGCGAACG CGTAACGCGA ATGGTGACGC GCGATCGTAA TCACCCGAGT GTGATCATCT
 GGTCGCTGGG GAATGAATCA GGCCACGGCG CTAATCACGA CGCGCTGTAT CGCTGGATCA
 AATCTGTGCA TCCTTCCCGC CCGGTGCGAGT ATGAAGGCGG CGGAGCCGAC ACCACGGCCA
 CCGATATTAT TTGCCCGATG TACGCGCGCG TGGATGAAGA CCAGCCCTTC CCGGCTGTGC
 CGAAATGGTC CATCAAAAAA TGGCTTTCGC TACCTGGAGA GACGCGCCCG CTGATCTGTTT
 GCGAATAGCG CCACGCGATG GGTAACAGTC TTGGCGGTTT CGCTAAATAC TGGCAGGCGT
 TTCGTCAGTA TCCCCGTTTA CAGGCGCGCT TCGTCTGGGA CTGGGTGGAT CAGTCGCTGA
 TTAAATATGA TGAAAACGGC AACCCTGGGT CGGCTTACGG CCGTGATTTT GGCGATACGC
 CGAACGATCG CCAGTTCTGT ATGAACGGTC TGGTCTTTGC CGACCGCACG CCGCATCCAG
 CGCTGACGGA AGCAAAACAC CAGCAGCAGT TTTTCCAGTT CCGTTTATCC GGGCAAACCA
 TCGAAGTGAC CAGCGAATAC CTGTTCCGTC ATAGCGATAA CGAGCTCCTG CACTGGATGG
 TGGCGCTGGA TGGTAAGCCG CTGGCAAGCG GTGAAGTGCC TCTGGATGTC GCTCCACAAG
 GTAAACAGTT GATTGAACTG CCTGAACTAC CGCAGCCGGA GAGCGCCGGG CAACTCTGGC
 TCACAGTACG CGTAGTGCAA CCGAACGCGA CCGCATGGTC AGAAGCCGGC CACATCAGCG
 CCTGGCAGCA GTGGCGTCTG GCGGAAAACC TCAGTGTGAC GCTCCCCGCC GCGTCCCACG
 CCATCCCGCA TCTGACCACC AGCGAAATGG ATTTTTCAT CGAGCTGGGT AATAAGCGTT
 GGCAATTTAA CCGCCAGTCA GGCTTCTCTT CACAGATGTG GATTGGCGAT AAAAAACAAC
 TGCTGACGCC GCTGCGCGAT CAGTTCACCC GTGCACCGCT GGATAACGAC ATTGGCGTAA
 GTGAAGCGAC CCGCATTTGAC CCTAACGCCT GGGTCGAACG CTGGAAGGCG GCGGGCCATT
 ACCAGGCCGA AGCAGCGTTG TTGCAGTGCA CGGCAGATAC ACTTGCTGAC GCGGTGCTGA
 TTACGACCGC TCACGCGTGG CAGCATCAGG GGAAAACCTT ATTTATCAGC CGGAAAACCT
 ACCGGATTGA TGGTAGTGGT CAAATGGCGA TTACCGTTGA TGTTGAAGTG GCGAGCGATA
 CACCGCATCC GCGCGGATT GGCTGAACT GCCAGCTGGC GCAGGTAGCA GAGCGGGTAA
 ACTGGCTCGG ATTAGGGCCG CAAGAAAACCT ATCCCGACCG CCTTACTGCC GCCTGTTTTG
 ACCGCTGGGA TCTGCCATTG TCAGACATGT ATACCCCGTA CGTCTTCCCG AGCGAAAACG
 GTCTGCGCTG CGGGACGCGC GAATTGAATT ATGGCCACA CCAGTGGCGC GGCGACTTCC
 AGTTCAACAT CAGCCGCTAC AGTCAACAGC AACTGATGGA AACCAGCCAT CGCCATCTGC
 TGCACGCGGA AGAAGGCACA TGGCTGAATA TCGACGGTTT CCATATGGGG ATTGGTGGAG
 ACGACTCCTG GAGCCCGTCA GTATCGGCGG AATTACAGCT GAGCGCCGGT CGCTACCATT
 ACCAGTTGGT CTGGTGTCAA AAATAGATTC TATAGTGTC CCTAAATGCT AGAGCTCGCT
 GATCAGCCTC GACTGTGCCT TCTAGTTGCC AGCCATCTGT TGTTTGCCCC TCCCCCGTGC
 CTTCTTGAC CCTGGAAGGT GCCACTCCCA CTGTCCTTTC CTAATAAAAT GAGGAAATTG
 CATCGCATTG TCTGAGTAGG TGTCATTCTA TTCTGGGGGG TGGGGTGGGG CAGGACAGCA
 AGGGG (SEQ ID NO:3)

FIGURE 6B

10/16




FIGURE 7

11/16

>Thy1_hB1cbs_IRES2_LacZ_BGHpolyA

```

GCGGCCGCTC TGGTTATCCA GGCTTCTGAA GGTTCAGCA AAGAAAGGGT TACAACCTTA
AAAGGAGAGC GTCCCGGGGT ATGGGTAGAA GACTGCTCCA CCCCACCCC CAGGGTCCCT
AACCGTCTTT TCCCTGGGCG AGTCAGCCCA ATCACAGGAC TGAGAGTGCC TCTTTAGTAG
CAGCAAGCCA CTTCGGACAC CCAAATGGAA CACCTCCAGT CAGCCCTCGC CGACCACCCC
ACCCCTCCA TCCTTTTCCC TCAGCCTCCG ATTGGCTGAA TCTAGAGTCC CTCCCTGCTC
CCCCCTCTCT CCCCACCCCT GGTGAAAAC TCGGGCTTCA GCGCTGGGTG CAGCAACTGG
AGGCGTTGGC GCACCAGGAG GAGGCTGCAG CTAGGGGAGT CCAGGTGAGA GCAGGCCGAC
GGGAGGGACC CGCACATGCA AGGACCGCCG CAGGGCGAGG ATGCAAGCCT TCCCCAGCTA
CAGTTTGGG AAAGGATACC AGGGCGCTCC TATATGGGGG CGCGGGAAC TGGGAAAGAA
GGTGCTCCCA GGTCGAGGTG GGAGAGGAAG GCAGTGCGGG GTCACGGGCT TTCTCCCTGC
TAACGACGCG TTTCGAAGAG TGGGTGCCGG AGGAGAACCA TGAGGAAGGA CATCAAGGAC
AGCCTTTGGT CCCCAGCTC AAATCGCTTT AGTGGTGCGA ATAGAGGGAG GAGGTGGGTG
GCAAACCTGA GGGAGTCCCC AGCGGGTGAC CTCGTGGCTG GCTGGGTGCG GGGCACCGCA
GGTAAGAAAA CCGCAATGTT GCGGGAGGGG ACTGGGTGGC AGGCGCGGGG GAGGGGAAAG
CTAGAAAGGA TGCGAGGGAG CGGAGGGGG AGGAGCGGG AGAATCTCAA CTGGTAGAGG
AAGATTAAAA TGAGGAAATA GCATCAGGGT GGGGTTAGCC AAGCCGGGCC TCAGGGAAG
GGCGCAAAGT TTGTCTGGGT GTGGGCTTAG GTGGGCTGGG TATGAGATTC GGGGCGCCGA
AAACACTGCT GCGCCTCTGC CAAATCACGC TACCCCTGTA TCTAGTTCTG CCAGGCTTCT
CCAGCCCCAG CCCCATTCT TTTCTCTAGT GTTCCCCCTT CCCTCCCTCG AATCTCAAGC
CCACACTCCC TCCTCCATAA CCCACTGTTA TCAAATCCAA GTCATTTGCC ACCCAACAAC
CATCAGGAGG CGGAAGCAGA CCGGAGGAGT TTGAGATCAA CTTGGGCTAC ATCACGAGTT
CCAGGCTCAC CAAGGCTTCT TAAGGAGACC TTGTCTCTAA AATTAATTAA TTAATTAATT
AATAGTCCCC TTTCTCTGCC ACAGAACCTT GGGATCTGGC TCCTGGTCGC AGCTCCCCC
ACCCAGGCT GACATTCAC TCCATAGCCC ATCCGGAAAT CCTAGTCTAT TTCCCCATGG
ATCTTGAAC GCAGAGAGAA TGGCAGAGTG GCGCGCCCTG TGCAAAGGAT GTTCCTAGCC
TAGGTGGAGC TCGCGAACTC GCAGACTGTG CCTCTCTTGG GCAAGGACAG CTAGACAGC
CTGCCGGTGT TTGAGCTAG GGCAGTGTG GGAAGGCAGA GAACCTGTGC AGGGCAGCAA
TGAACACAGG ACCAGAAAC TGCAGCCCTA GGAACACTCA AGAGCTGGCC ATTTGCAAGC
ATCTCTGGCC TCCGTGCTTC TCACTCATGT CCCATGTCTT ATACAGGCCT CTGTGGCACC
TCGCTTGCC TATCTCATCC CTAGCCGTTA AGCTTTCTGC ATGACTTATC ACTTGGGGCA
TAATGCTGGA TACCTACCAT TTTCTTAGAC CCCATCAAAA TCCTATTTGA GTGTACGGTT
CGGAGAACC TATTTATCCG GTAAATGTCT TTTACTCTGC TCTCAGGGAG CTGAGGCAGG
ACATCCTGAG ATACATTGGG AGAGGAGATA CAGTTTCAAT AAAATAATAG GTTGGGTGGA
GGTACATGCC TATAATGCCA CCACTCAGGA AATGGTGGA GCTTCGTGAG TTTGAGGCCA
ACCCAAGAAA CATAGTGAAC CCCTGTGAGT AAATAAGTAA GCAAGTATTT GAGTATCTAC
TATATGCTAG GGCTGACCTG GACATTAGGG GTCATCTTCT GAACAACTA GTGCTTGAGG
GAGGTATTTG GGGTTTTTGT TTGTTAATG GATCTGAATG AGTTCCAGAG ACTGGCTACA
CAGCGATATG ACTGAGCTTA ACACCCCTAA AGCATAAGT CAGACCAATT AGACAATAAA
AGGTATGTAT AGCTTACCAA ATAAAAAAT TGTATTTTCA AGAGAGTGTC TGTCTGTGTA
GCCCTGGCTG TTCTTGAAC TACTCTGTAG ACCAGGCTGG CCTGGAAATC CATCTGCCTG
CCTCTGCCTC TCTGCCTCTC TGCCCTCTCT TGCCCTCTCT TGCCCTCTCT TGCCCTCTCT
TGCCCTCTCT TGCCCTCTCT TGCCCTCTCT TCTGCCCTCT GGCCTCTGGC CTCTGCCTCT
CCTCTGCCCCT CTGGCCTCTG GCCTCTGCCC TCTGCCCCTC GGCCTCTGGC CTCTGCCTCT
GCCTCTTGAG TGCTGGAATC AAAGGTGTGA GCTCTGTAGG TCTTAAGTTC CAGAAGAAAG
TAATGAAGTC ACCCAGCAGG GAGGTGCTCA GGGACAGCAC AGACACACAC CCAGGACATA
GGCTCCCACT TCCTTGCTTT TCTCTGAGTG GCAAAGGACC TTAGGCAGTG TCACTCCCTA
AGAGAAGGGG ATAAAGAGAG GGGCTGAGGT ATTCATCATG TGCTCCGTGG ATCTCAAGCC
CTCAAGGTAA ATGGGGACCC ACCTGTCCCTA CCAGCTGGCT GACCTGTAGC TTTCCCACC
ACAGAATCCA AGTCGGAAC CTGGGCACAA GCTTGGTACC GCCGCCACCA TGGCATCATC
CTGGCCCCCT CTAGAGCTCC AATCCTCCAA CCAGAGCCAG CTCTTCCCTC AAAATGCTAC

```

FIGURE 8A

12/16

GGCCTGTGAC	AATGCTCCAG	AAGCCTGGGA	CCTGCTGCAC	AGAGTGCTGC	CGACATTTAT
CATCTCCATC	TGTTTCTTCG	GCCTCCTAGG	GAACCTTTTT	GTCCTGTTGG	TCTTCCTCCT
GGCCCGGCGG	CAACTGAACG	TGGCAGAAAT	CTACCTGGCC	AACCTGGCCG	CCTCTGATCT
GGTGTGTTGTC	TTGGGCTTGC	CCTTCTGGGC	AGAGAATATC	TGGAACCAGT	TTAACTGGCC
TTTCGGAGCC	CTCCTCTGCC	GTGTCATCAA	CGGGGTCATC	AAGGCCAATT	TGTTTCATCAG
CATCTTCCTG	GTGGTGGCCA	TCAGCCAGGA	CCGCTACCGC	GTGCTGGTGC	ACCCTATGGC
CAGCCGGAGG	CAGCAGCGGC	GGAGGCAGGC	CCGGGTCACC	TGCGTGCTCA	TCTGGGTTGT
GGGGGGCCTC	TTGAGCATCC	CCACATTCCCT	GCTGCGATCC	ATCCAAGCCG	TCCCAGATCT
GAACATCACC	GCCTGCATCC	TGCTCCTCCC	CCATGAGGCC	TGGCACTTTG	CAAGGATTGT
GGAGTTAAAT	ATTCTGGGTT	TCCTCCTACC	ACTGGCTGCG	ATCGTCTTCT	TCAACTACCA
CATCCTGGCC	TCCCTGCGAA	CGCGGGAGGA	GGTCAGCAGG	ACAAGGTGCG	GGGGCCGCAA
GGATAGCAAG	AACACAGCGC	TGATCCTCAC	GCTCGTGGTT	GCCTTCCTGG	TCTGCTGGGC
CCCTTACCAC	TTCTTTGCCT	TCCTGGAATT	CTTATTCCAG	GTGCAAGCAG	TCCGAGGCTG
CTTTTGGGAG	GACTTCATTG	ACCTGGGCCT	GCAATTGGCC	AACTTCTTTG	CCTTCACTAA
CAGCTCCCTG	AATCCAGTAA	TTTATGTCTT	TGTGGGCCGG	CTCTTCAGGA	CCAAGGTCTG
GGAACTTTAT	AAACAATGCA	CCCCTAAAAG	TCTTGCTCCA	ATATCTTCAT	CCCATAGGAA
AGAAATCCTT	CAACTTTTCT	GGCGGAATTA	ATGCAGTCGA	CGGTACCGCG	GGCCCGGGAT
CCGCCCCCTCT	CCCTCCCCCC	CCCCTAACGT	TACTGGCCGA	AGCCGCTTGG	AATAAGGCCG
GTGTGCGTTT	GTCTATATGT	TATTTTCCAC	CATATTGCCG	TCTTTTGGCA	ATGTGAGGGC
CCGGAACCTT	GGCCCTGTCT	TCTTGACGAG	CATTCTAGG	GGTCTTTCCC	CTCTCGCCAA
AGGAATGCAA	GGTCTGTTGA	ATGTCGTGAA	GGAAGCAGTT	CCTCTGGAAG	CTTCTTGAAG
ACAAACAACG	TCTGTAGCGA	CCCTTTGCAG	GCAGCGGAAC	CCCCACCTG	GCGACAGGTG
CCTCTGCGGC	CAAAAGCCAC	GTGTATAAGA	TACACCTGCA	AAGGCGGCAC	AACCCAGTGT
CCACGTTGTG	AGTTGGATAG	TTGTGGAAAG	AGTCAAATGG	CTCTCCTCAA	GCGTATTCAA
CAAGGGGCTG	AAGGATGCCC	AGAAGGTACC	CCATTGTATG	GGATCTGATC	TGGGGCCTCG
GTACACATGC	TTTACATGTG	TTTAGTCGAG	GTTAAAAAAA	CGTCTAGGCC	CCCCGAACCA
CGGGGACGTG	GTTTTCCCTT	GAAAAACACG	ATGATAATAT	GGCCACAACC	ATGATAGATC
CCGTCTGTTTT	ACAACGTCGT	GACTGGGAAA	ACCCTGGCGT	TACCCAACCT	AATCGCCTTG
CAGCACATCC	CCCTTTCGCC	AGCTGGCGTA	ATAGCGAAGA	GGCCCGCACC	GATCGCCCTT
CCCAACAGTT	GCGCAGCCTG	AATGGCGAAT	GGCGCTTTGC	CTGGTTTCCG	GCACCAGAAG
CGGTGCCGGA	AAGCTGGCTG	GAGTGCGATC	TTCTTGAGGC	CGATACTGTC	GTCTGCCCTT
CAAACTGGCA	GATGCACGGT	TACGATGCGC	CCATCTACAC	CAACGTGACC	TATCCCATTA
CGGTCAATCT	GCCGTTTGTG	CCCACGGAGA	ATCCGACGGG	TTGTTACTCG	CTCACCTTTA
ATGTTGATGA	AAGCTGGCTA	CAGGAAGGCC	AGACGCGAAT	TATTTTTGAT	GGCGTTAACT
CGGCGTTTCA	TCTGTGGTGC	AACGGGCGCT	GGGTGCGTTA	CGGCCAGGAC	AGTCGTTTGC
CGTCTGAATT	TGACCTGAGC	GCATTTTAC	GCGCCGGAGA	AAACCGCCTC	GCGGTGATGG
TGCTGCGCTG	GAGTGACGGC	AGTTATCTGG	AAGATCAGGA	TATGTGGCGG	ATGAGCGGCA
TTTTCCGTGA	CGTCTCGTTG	CTGCATAAAC	CGACTACACA	AATCAGCGAT	TTCCATGTTG
CCACTCGCTT	TAATGATGAT	TTCAGCCGCG	CTGTACTGGA	GGCTGAAGTT	CAGATGTGCG
GCGAGTTGCG	TGACTACCTA	CGGGTAACAG	TTTCTTTATG	GCAGGGTGAA	ACGCAGGTGC
CCAGCGGCAC	CGCGCCTTTC	GGCGGTGAAA	TTATCGATGA	GCGTGGTGGT	TATGCCGATC
GCGTCACACT	ACGTCTGAAC	GTCGAAAACC	CGAAACTGTG	GAGCGCCGAA	ATCCCGAATC
TCTATCGTGC	GGTGGTTGAA	CTGCACACCC	CCGACGGCAC	GCTGATTGAA	GCAGAAGCCT
GCGATGTGCG	TTTCCGCGAG	GTGCGGATTG	AAAATGGTCT	GCTGCTGCTG	AACGGCAAGC
CGTTGCTGAT	TCGAGGCGTT	AACCGTCACG	AGCATCATCC	TCTGCATGGT	CAGGTCATGG
ATGAGCAGAC	GATGGTGCAG	GATATCCTGC	TGATGAAGCA	GAACAACTTT	AACGCCGTGC
GCTGTTTCGCA	TTATCCGAAC	CATCCGCTGT	GGTACACGCT	GTGCGACCGC	TACGGCCTGT
ATGTGGTGGA	TGAAGCCAAT	ATTGAAACCC	ACGGCATGGT	GCCAATGAAT	CGTCTGACCG
ATGATCCGCG	CTGGCTACCG	GCGATGAGCG	AACGCGTAAC	GCGAATGGTG	CAGCGCGATC
GTAATCACCC	GAGTGTGATC	ATCTGGTCGC	TGGGGAATGA	ATCAGGCCAC	GGCGCTAATC
ACGACGCGCT	GTATCGCTGG	ATCAAATCTG	TCGATCCTTC	CCGCCCCTTG	CAGTATGAAG
GCGGCGGAGC	CGACACCACG	GCCACCGATA	TTATTTGCC	GATGTACGCG	CGCGTGGATG
AAGACCAGCC	CTTCCCCTGG	GTGCCGAAAT	GGTCCATCAA	AAAATGGCTT	TCGCTACCTG
GAGAGACGCG	CCCGCTGATC	CTTTGCGAAT	ACGCCCACGC	GATGGGTAAAC	AGTCTTGGCG
GTTTCGCTAA	ATACTGGCAG	GCGTTTCGCT	AGTATCCCCG	TTTACAGGGC	GCGTTCGTCT
GGGACTGGGT	GGATCAGTCG	CGATTAAAT	ATGATGAAAA	CGGCAACCCG	TGGTGGGCTT
ACGGCGGTGA	TTTTGGCGAT	ACGCCGAACG	ATCGCCAGTT	CTGTATGAAC	GGTCTGGTCT

FIGURE 8B

13/16

```
TTGCCGACCG CACGCCGCAT CCAGCGCTGA CGGAAGCAAA ACACCAGCAG CAGTTTTTCC
AGTTCCGTTT ATCCGGGCAA ACCATCGAAG TGACCAGCGA ATACCTGTTC CGTCATAGCG
ATAACGAGCT CCTGCACTGG ATGGTGCGC TGGATGGTAA GCCGCTGGCA AGCGGTGAAG
TGCCTCTGGA TGTCGCTCCA CAAGGTAAAC AGTTGATTGA ACTGCCTGAA CTACCGCAGC
CGGAGAGCGC CGGGCAACTC TGGCTCACAG TACGCGTAGT GCAACCGAAC GCGACCGCAT
GGTCAGAAGC CGGCCACATC AGCGCTGGC AGCAGTGGCG TCTGGCGGAA AACCTCAGTG
TGACGCTCCC CGCCGCGTCC CACGCCATCC CGCATCTGAC CACCAGCGAA ATGGATTTTT
GCATCGAGCT GGGTAATAAG CGTTGGCAAT TTAACCGCCA GTCAGGCTTT CTTTCACAGA
TGTGGATTGG CGATAAAAAA CAACTGCTGA CGCCGCTGCG CGATCAGTTC ACCCGTGCAC
CGCTGGATAA CGACATTGGC GTAAGTGAAG CGACCCGCAT TGACCCTAAC GCCTGGGTCG
AACGCTGGAA GCGCGCGGGC CATTACCAGG CCGAAGCAGC GTTGTTGCAG TGCACGGCAG
ATACACTTGC TGACGCGGTG CTGATTACGA CCGCTCACGC GTGGCAGCAT CAGGGGAAAA
CCTTATTTAT CAGCCGGA AAA ACCTACCGGA TTGATGGTAG TGGTCAAATG GCGATTACCG
TTGATGTTGA AGTGGCGAGC GATACACCGC ATCCGGCGCG GATTGGCCTG AACTGCCAGC
TGGCGCAGGT AGCAGAGCGG GTAAACTGGC TCGGATTAGG GCCGCAAGAA AACTATCCCG
ACCGCCTTAC TGCCGCCTGT TTTGACCGCT GGGATCTGCC ATTGTCAGAC ATGTATACCC
CGTACGTCTT CCCGAGCGAA AACGGTCTGC GCTGCGGGAC GCGCGAATTG AATTATGGCC
CACACCAGTG GCGCGGCGAC TTCCAGTTCA ACATCAGCCG CTACAGTCAA CAGCAACTGA
TGGAAACCAG CCATCGCCAT CTGCTGCACG CGGAAGAAGG CACATGGCTG AATATCGACG
GTTTCCATAT GGGGATTGGT GGAGACGACT CCTGGAGCCC GTCAGTATCG GCGGAATTAC
AGCTGAGCGC CGGTCGCTAC CATTACCAGT TGGTCTGGTG TCAAAAATAG ATTCTATAGT
GTCACCTAAA TGCTAGAGCT CGCTGATCAG CCTCGACTGT GCCTTCTAGT TGCCAGCCAT
CTGTTGTTTG CCCCTCCCC GTGCCTTCCT TGACCCTGGA AGGTGCCACT CCCACTGTCC
TTTCCTAATA AAATGAGGAA ATTGCATCGC ATTGTCTGAG TAGGTGTCAT TCTATTCTGG
GGGGTGGGGT GGGGCAGGAC AGCAAGGGGG AGGATTGGGA AGACAATAGC AGGCATGCTG
GGGAGCGGCC GC (SEQ ID NO:4)
```

FIGURE 8C

14/16

Rat 1810




FIGURE 9A

Rat 1813





FIGURE 9B

15/16

**FIGURE 9C**

16/16




FIGURE 10

SEQUENCE LISTING

<110> Hess, John W.
Gould, Robert J.
Pettibone, Douglas J.

<120> TRANSGENIC RODENTS AS ANIMAL MODELS FOR
MODULATION OF B1 BRADYKININ RECEPTOR PROTEIN

<130> 20945Y

<150> US 60/313,531

<151> 2001-08-20

<160> 41

<170> FastSEQ for Windows Version 4.0

<210> 1

<211> 4132

<212> DNA

<213> human

<400> 1

ggatcctgag	ctcctcctct	gctcgcccaa	tccttccaac	cccctatggt	ggtatggctg	60
acacagaaaa	tgtctgctcc	tgtatgggac	atttgcccct	cttctccaaa	tataagacag	120
gatgaggcct	agcttttgct	gctccaaagt	tttaaaagaa	cacattgcac	ggcatttagg	180
gactctaaag	ggtggaggag	gaatgaggga	attgcatcat	gccaaaggctg	gtcctcatcc	240
atcactgctt	ccagggccca	gagtggcttc	caggaagtat	tcttaciaaag	gaagcccgat	300
ctgtagctaa	cactcagagc	ccattttcct	gcgttaaccc	ctcccgcacct	catatacagg	360
agtaacatga	tcagtgcacct	gggggagctg	gccaaactgc	gggacctgcc	caagctgagg	420
gccttggtgc	tgctggacaa	cccctgtgcc	gatgagactg	actaccgcca	ggaggccctg	480
gtgcagatgg	cacacctaga	gcgcctagac	aaagagtact	atgaggacga	ggaccgggca	540
gaagctgagg	agatccgaca	gaggctgaag	gaggaacagg	agcaagaact	cgaccgggac	600
caagacatgg	aaccgtacct	cccgccaaact	tagtggctcc	tctagcctgc	agggacagta	660
aagggtgatgg	caggaaggca	gtccccggag	gtcaaaggct	gggcacgcgg	gaggagaggc	720
cagagtcaga	ggctgcgggt	atctcagata	tgaaggaaaag	atgagagagg	ctcaggaaga	780
ggtaagaaaa	gacacaagag	accagagaag	ggagaagaat	tagagaggga	ggcagaggac	840
cgctgtctct	acagacatag	ctggtagaga	ctgggaggaa	gggatgaacc	ctgagcgcat	900
gaagggaaag	aggtggctgg	tggtatatgg	aggatgtagc	tgggccaggg	aaaagatcct	960
gcactaaaaa	tctgaagcta	aaaataacag	gacacggggg	ggagaggcga	aaggaggggca	1020
gagtgaggca	gagagactga	gaggcctggg	gatgtgggca	ttccggtagg	gcacacagtt	1080
cacttgtctt	ctctttttcc	aggaggccaa	agatgctgac	gtcaagaact	cataataccc	1140
cagtggggac	caccgcattc	atagccctgt	tacaagaagt	gggagatggt	cctttttgtc	1200
ccagactgga	aatccgttac	atccccgaggc	tcaggttctg	tgggtggcat	ctctgtgtgg	1260
cttggtctgt	gggcctacct	aaagtcctaa	gcacagctct	caagcagatc	cgaggcgact	1320
aagatgctag	taggggttgt	ctggagagaa	gagccgagga	ggtgggctgt	gatggatcag	1380
ttcagctttc	aaataaaaag	gcgtttttat	attctgtgtc	gagttcgtga	acccctgtgg	1440
tgggcttctc	catctgtctg	ggtagtacc	tgccactata	ctggaataag	gggacgcctg	1500
cttccctcga	gttggctgga	caaggttatg	agcatccgtg	tacttatggg	gttgccagct	1560
tggtcctgga	tcgcccgggc	ccttccccca	cccgctcggt	tccccaccac	caccgcgct	1620
cgtacgtgcg	tctccgcctg	cagctcttga	ctcatcgggg	cccccgggtc	acatgcgctc	1680
gctcggtctt	ataggcgccg	ccccctgccc	accccccgcc	cgcgctggga	gccgcagccg	1740
ccgccactec	tgctctctct	gcgcccgcgc	cgtcaccacc	gccaccgcca	ccggctgagt	1800
ctgcagctct	cgaggtaagt	accgcctata	gactctatag	gcacaccctt	ttggctctta	1860
tgcatgctat	actgtttttg	gcttggggcc	tatacacccc	cgcttcctta	tgctataggt	1920
gatggtatag	cttagcctat	aggtgtgggt	tattgaccat	tattgaccac	tcccctattg	1980
gtgacgatac	tttccattac	taatccataa	catggctctt	tgccacaact	atctctattg	2040

gctatatgcc	aatactctgt	ccttcagaga	ctgacacgga	ctctgtatatt	ttacaggatg	2100
gggtccatt	tattatttac	aaattcacat	atacaacaac	gccgtcccc	gtgcccgcag	2160
ttttatttaa	acatagcgtg	ggatctccac	gcgaatctcg	ggtacgtgtt	ccggacatgg	2220
gctcttctcc	ggtagcggcg	gagcttccac	atccgagccc	tggtcccatg	cctccagcgg	2280
ctcatggctg	ctcggcagct	ccttgctcct	aacagtggag	gccagactta	ggcacagcac	2340
aatgcccacc	accaccagtg	tgccgcacaa	ggcctgtggc	gtaggggatg	tgtctgaaaa	2400
tgagcgtgga	gattgggctc	gcacggctga	cgcagatgga	agacttaagg	cagcggcaga	2460
agaagatgca	ggcagctgag	ttgttggtatt	ctgataagag	tcagaggtaa	ctcccgttgc	2520
ggtgctgtta	acggtggagg	gcagtgtagt	ctgagcagta	ctcgttgctg	ccgcgcgcgc	2580
caccagacat	aatagctgac	agactaacag	actgttccct	tccatgggtc	ttttctgcag	2640
aagcttggtg	ccgcccgcac	catggcatca	tcctggcccc	ctctagagct	ccaatcctcc	2700
aaccagagcc	agctcttccc	tcaaaatgct	acggcctgtg	acaatgctcc	agaagcctgg	2760
gacctgtcgc	acagagtgtc	gccgacattt	atcatctcca	tctgtttctt	cggcctccta	2820
gggaaccttt	ttgtcctgtt	ggtcttccct	ctgccccggc	ggcaactgaa	cgtggcagaa	2880
atctacctgg	ccaacctggc	agcctctgat	ctgggtgttg	tcttgggctt	gcccttctgg	2940
gcagagaata	tctggaacca	gtttaactgg	cctttcggag	ccctcctctg	ccgtgtcatc	3000
aacggggtca	tcaaggccaa	tttgttcata	agcatcttcc	tggtgggtggc	catcagccag	3060
gaccgctacc	gcgtgctggt	gcaccctatg	gccagccgga	ggcagcagcg	gaggaggcag	3120
gcccgggtca	cctgcgtgct	catctgggtt	gtggggggcc	tcttgagcat	ccccacattc	3180
ctgctgcgat	ccatccaagc	cgctccagat	ctgaacatca	ccgcctgcat	cctgctcctc	3240
ccccatgagg	cctggcactt	tgcaaggatt	gtggagttaa	atattctggg	tttctctcta	3300
ccactggctg	cgatcgtctt	cttcaactac	cacatcctgg	cctccctgcg	aacgcgggag	3360
gaggtcagca	ggacaagggtg	cggggggccgc	aaggatagca	agaccacagc	gctgatcctc	3420
acgctcgtgg	ttgccttcct	ggtctgctgg	gccccttacc	acttctttgc	cttcttgga	3480
ttcttattcc	aggtgcaagc	agtccgaggg	tgcttttggg	aggacttcat	tgacctgggc	3540
ctgcaattgg	ccaacttctt	tgcttctact	aacagctccc	tgaatccagt	aatttatgtc	3600
tttgtgggcc	ggctcttcag	gaccaagggtc	tggaactttt	ataaacaatg	caccctaaa	3660
agtcttgctc	caatatcttc	atcccatagg	aaagaaatct	tccaactttt	ctggcggaat	3720
taaaacagca	ttgaaccaag	aagcttggtc	ttcttatcaa	ttctttgtga	cataataaat	3780
gctattgtga	taggctaaat	gattactccc	gtagattggg	gggtaccta	tccctggact	3840
tgatgagcgg	cctcgagcat	gcatctagag	ggccctatct	tatagtgtca	cctaaatgct	3900
agagctcgct	gatcagcctc	gactgtgcct	tctagtgtgc	agccatctgt	tgtttgcccc	3960
tcccccgctg	cttccttgac	cctggaagggt	gccactccca	ctgtcctttc	ctaataaaaat	4020
gaggaaattg	catcgcattg	tctgagtagg	tgtcattcta	ttctgggggg	tgggggtggg	4080
caggacagca	agggggagga	ttgggaagac	aatagcaggc	atgctgggat	cc	4132

<210> 2
 <211> 1605
 <212> DNA
 <213> human

<400> 2						
gccgccccct	gcccaccccc	cgcccgcgct	gggagccgca	gccgcccgca	ctcctgctct	60
ctctgcgcgc	ccgcgctcac	caccgccacc	gccaccggt	gagtctgcag	tcctcgagaa	120
gcttggtacc	gccgccacca	tggtcatcat	ctggccccct	ctagagctcc	aatcctccaa	180
ccagagccag	ctcttccctc	aaaatgctac	ggcctgtgac	aatgctccag	aagcctggga	240
cctgctgcac	agagtgtcgc	cgacatttat	catctccatc	tgtttcttcg	gcctcctagg	300
gaaccttttt	gtcctgttgg	tcttccctct	gccccggcgg	caactgaacg	tggcagaaat	360
ctacctggcc	aacctggcag	cctctgatct	ggtgtttgtc	ttgggcttgc	ccttctgggc	420
agagaatatc	tggaaaccagt	ttaactggcc	tttcggagcc	ctcctctgcc	gtgtcatcaa	480
cggggctcatc	aaggccaatt	tgttcatcag	catcttctct	gtggtggcca	tcagccagga	540
ccgtaccgc	gtgctgggtc	accctatggc	cagccggagg	cagcagcggc	ggaggcaggc	600
ccgggtcacc	tgctgtgtca	tctgggttgt	ggggggcctc	ttgagcatcc	ccacattcct	660
gctgcgatcc	atccaagccg	tcccagatct	gaacatcacc	gcctgcatcc	tgctcctccc	720
ccatgaggcc	tggcactttg	caaggattgt	ggagttaa	attctgggtt	tcctcctacc	780
actggctgcg	atcgtcttct	tcaactacca	catcctggcc	tccttgcgaa	cgcgaggaga	840
ggtcagcagg	acaagggtgc	ggggccgcaa	ggatagcagc	accacagcgc	tgatcctcac	900
gctcgtggtt	gccttcctgg	tctgctgggc	cccttaccac	ttctttgcct	tcttggaatt	960
cttattccag	gtgcaagcag	tccgaggctg	cttttgggag	gacttcattg	acctgggcct	1020
gcaattggcc	aacttctttg	ccttcactaa	cagctccctg	aatccagtaa	tttatgtctt	1080

tgtgggcccgg	ctcttcagga	ccaaggtctg	ggaactttat	aaacaatgca	cccctaaaag	1140
tcttgctcca	atatcttcat	cccataggaa	agaaatcttc	caacttttct	ggcggaatta	1200
aaacagcatt	gaaccaagaa	gcttggcttt	cttatcaatt	ctttgtgaca	taataaatgc	1260
tattgtgata	ggctaaatga	ttactcccg	agattggggg	gtacctaatc	cctggacttg	1320
atgacgctcg	agcatgcatc	tagagggccc	tattctatag	tgtcacctaa	atgctagagc	1380
tcgctgatca	gcctcgactg	tgcttcttag	ttgccagcca	tctgttgttt	gccccctccc	1440
cgtgccttcc	ttgaccttgg	aaggtgccac	tcccactgtc	ctttccta	aaaatgagga	1500
aattgcatcg	cattgtctga	gtaggtgtca	ttctattctg	gggggtgggg	tggggcagga	1560
cagcaagggg	gaggattggg	aagacaatag	caggcatgct	gggga		1605

<210> 3

<211> 6485

<212> DNA

<213> human

<400> 3

ggccgcgat	gtacgggcca	gatatacgcg	ttgacattga	ttattgacta	gttattaata	60
gtaatacaatt	acgggggtcat	tagttcatag	cccatatag	gagttccg	ttacataact	120
tacggtaaat	ggccgcctg	gctgaccg	caacgacccc	cgccattga	cgtcaataat	180
gacgtatgtt	cccatagtaa	cgccaatagg	gactttccat	tgacgtcaat	gggtggagta	240
tttacggtaa	actgcccact	tggcagtaca	tcaagtgtat	catatgccaa	gtacgcccc	300
tattgacgtc	aatgacggta	aatggcccg	ctggcattat	gcccagtaca	tgaccttatg	360
ggacttttct	acttggcagt	acatctacgt	attagtcac	gctattacca	tggtgatg	420
gttttggcag	tacatcaatg	ggcgtggata	gcggtttgac	tcacggggat	ttccaagtct	480
ccaccccat	gacgtcaatg	ggagtttgtt	ttggcaccaa	aatcaacggg	actttccaaa	540
atgtcgtaac	aactccgccc	cattgacgca	aatgggcgg	aggcgtgtac	ggtgggaggt	600
ctatataagc	agagctctct	ggctaactag	agaacccact	gcttactggc	ttatcgaaat	660
taatacgact	cactataggt	aagtaccg	tatagactct	ataggcacac	ccctttggct	720
cttatgcatg	ctatactgtt	tttggcttgg	ggcctatata	ccccgccttc	cttatgctat	780
agggtatggt	atagcttagc	ctataggtgt	gggttattga	ccattattga	ccactcccct	840
attggtgacg	atactttcca	ttactaatcc	ataacatggc	tctttgccac	aactatctct	900
attggctata	tgccaatact	ctgtccttca	gagactgaca	cggactctgt	atttttacag	960
gatgggggtcc	cattttattat	ttacaaattc	acatatacaa	caacgccgtc	ccccgtgccc	1020
gcagttttta	ttaaacatag	cgtgggatct	ccacgcgaat	ctcgggtacg	tggtccggac	1080
atgggtctct	ctccggtagc	ggcggagctt	ccacatacga	gccctgggtc	catgctcca	1140
gcggctcatg	agctcctggc	agctccttgc	tcctaacagt	ggaggccaga	cttaggcaca	1200
gcacaatgcc	caccaccacc	agtgtgccgc	acaaggccgt	ggcggtagg	tatgtgtctg	1260
aaaatgagcg	tggagattgg	gctcgcacgg	ctgacgcaga	tggagactt	aaggcagcgg	1320
cagaagaaga	tgcaggcagc	tgagtgtgtg	tattctgata	agagtcagag	gtaactccc	1380
ttgcggtgtc	gttaacgggt	gagggcagt	tagtctgagc	agtactcgtt	gctgcgcgc	1440
gcgcaccag	acataatagc	tgacagacta	acagactgtt	ctttccatg	ggtctttct	1500
gcagaagctt	ggtaccgccc	ccaccatggc	atcatcctgg	ccccctctag	agctccaatc	1560
ctccaaccag	agccagctct	tccctcaaaa	tgctacggcc	tgtgacaatg	ctccagaagc	1620
ctgggacctg	ctgcacagag	tgctgccgac	atttatcact	tccatctgtt	tcttcggcct	1680
cctagggaac	ctttttgtcc	tggttggtctt	cctcctgccc	cggcggaac	tgaacgtggc	1740
agaaatctac	ctggccaacc	tggcagcctc	tgatctggtg	tttgtcttgg	gcttgccctt	1800
ctgggcagag	aatatcttga	accagttaaa	ctggcctttc	ggagccctcc	tctgcctgt	1860
catcaacggg	gtcatcaagg	ccaatttgtt	catcagcatc	ttcctggtgg	tggccatcag	1920
ccaggaccgc	taccgcgtgc	tgggtgcacc	tatggccagc	cggaggcagc	agcggcggag	1980
gcaggccccg	gtcacctg	tgctcatctg	ggttgtgggg	ggcctcttga	gcacccccc	2040
attcctgtctg	cgatccatcc	aagccgtccc	agatctgaac	atcacgcct	gcacctctgt	2100
cctcccccat	gaggcctggc	actttgcaag	gattgtggag	ttaaatattc	tgggtttcct	2160
cctaccactg	gctgcgatcg	tcttcttcaa	ctaccacatc	ctggcctccc	tgcgaacg	2220
ggaggagggtc	agcaggacaa	ggtgcggggg	ccgcaaggat	agcaagacca	cagcgctgat	2280
cctcacgctc	gtggttgcc	tcctggtctg	ctgggcccc	taccacttct	ttgccttct	2340
ggaattctta	ttccagggtg	aagcagtc	aggctgcttt	tgggaggact	tcattgacct	2400
gggcctgcaa	ttggccaact	tctttgcctt	cactaacagc	tccctgaatc	cagtaattta	2460
tgtctttgtg	ggcgggctct	tcaggaccaa	ggtctgggaa	ctttataaac	aatgacccc	2520
taaaagtctt	gctccaatat	cttcatccca	taggaaagaa	atcttccaac	ttttctggcg	2580
gaattaatgc	agtcgacggt	accgcggggc	cgggatccgc	ccctctccct	cccccccc	2640

taacgttact	ggccgaagcc	gcttgaata	aggccggtgt	gcgtttgtct	atatgttatt	2700
ttccaccata	ttgccgtctt	ttggcaatgt	gagggcccg	aaacctggcc	ctgtcttctt	2760
gacgagcatt	cctaggggtc	tttcccctct	cgccaaagga	atgcaaggct	tgttgaatgt	2820
cgtgaaggaa	gcagttcctc	tggaagcttc	ttgaagacaa	acaacgtctg	tagcgaccct	2880
ttgcaggcag	cggaaccccc	cacctggcga	caggtgcctc	tgcggccaaa	agccacgtgt	2940
ataagataca	cctgcaaagg	cggcacaacc	ccagtgccac	gttgtgagtt	ggatagttgt	3000
ggaaagagtc	aaatggctct	cctcaagcgt	attcaacaag	gggctgaagg	atgccagaa	3060
ggtaccccat	tgtatgggat	ctgatctggg	gcctcggtag	acatgcttta	catgtgttta	3120
gtcgaggtta	aaaaaacgtc	taggcccccc	gaaccacggg	gacgtggttt	tcctttgaaa	3180
aacacgatga	taatatggcc	acaaccatga	tagatcccgt	cgttttacaa	cgctcgtgact	3240
gggaaaaccc	tggcgttacc	caacttaatc	gccttgccgc	acatccccct	ttcgccagct	3300
ggcgtaatag	cgaagaggcc	cgcaccgatc	gcccttccca	acagttgcgc	agcctgaatg	3360
gcgaatggcg	ctttgcctgg	tttccggcac	cagaagcggg	gccggaaagc	tggctggagt	3420
gcgatcttcc	tgaggccgat	actgtcgtcg	tcccccaaaa	ctggcagatg	cacggttacg	3480
atgcgccccat	ctacaccaac	gtgacctatc	ccattacggg	caatccgccg	tttgttccca	3540
cggagaatcc	gacgggttgt	tactcgtcga	cctttaatgt	tgatgaaagc	tggctacagg	3600
aaggccagac	gcgaattatt	tttgatggcg	ttaactcggc	gtttcatctg	tgggtcaacg	3660
ggcgctgggt	cggttacggc	caggacagtc	gtttgcgcgt	tgaatttgac	ctgagcgcat	3720
ttttacgcgc	cggagaaaac	cgcctcgcgg	tgatgggtgt	gcgctggagt	gacggcagtt	3780
atctggaaga	actgtggagc	tggcggatga	gcggcatttt	ccgtgacgtc	tcgttgctgc	3840
ataaaccgac	tacacaaatc	agcgatttcc	atgttgccac	tcgctttaat	gatgatttca	3900
gccgcgctgt	actggaggct	gaagttcaga	tgtgcggcga	gttgcgtagc	tacctacggg	3960
taacagtttc	tttatggcag	ggtgaaacgc	aggctgccag	cggcacccgcg	cctttcggcg	4020
gtgaaattat	cgatgagcgt	ggtggttatg	ccgatcgcgt	cacactacgt	ctgaacgtcg	4080
aaaacccgaa	actgtggagc	gccgaaatcc	cgaatctcta	tcgtgcggtg	gttgaactgc	4140
acaccgccga	cggcacgctg	attgaagcag	aagcctgcga	tgtcggtttc	cgcgaggtgc	4200
ggattgaaaa	tggctctgctg	ctgctgaacg	gcaagccggt	gctgattcga	ggcgtaaac	4260
gtcacgagca	tcattcctctg	catggtcagg	tcattggatga	gcagacgatg	gtgcaggata	4320
tcctgctgat	gaagcagaac	aactttaacg	ccgtgcgctg	ttcgcatat	ccgaaccatc	4380
cgctgtggta	cacgctgtgc	gaccgctacg	gcctgtatgt	ggtggatgaa	gccaatattg	4440
aaaccccgag	catggtgcga	atgaatcgtc	tgaccgatga	tcgcgcgtgg	ctaccggcga	4500
tgagcgaacg	cgtaacgcga	atggtgcagc	gcgatcgtaa	tcacccgagt	gtgatcatct	4560
ggtcgcgtgg	gaatgaatca	ggccacggcg	ctaatacaga	cgcgctgtat	cgctggatca	4620
aatctgtcga	tccttcccgc	ccggtgcagt	atgaaggcgg	cggagccgac	accacggcca	4680
ccgatattat	ttgcccgatg	tacgcgcgcg	tggatgaaga	ccagcccttc	ccggctgtgc	4740
cgaatgggtc	catcaaaaaa	tggctttcgc	tacctggaga	gacgcgcccg	ctgactcttt	4800
gcgaatacgc	ccacgcgatg	ggtaacagtc	ttggcggttt	cgctaaatac	tggcaggcgt	4860
ttcgtcagta	ttcccgttta	cagggcggct	tcgtctggga	ctgggtggat	cagtcgctga	4920
ttaaatatga	tgaaaacggc	aacccgtggt	cggcttacgg	cggtgatttt	ggcgatacgc	4980
cgaacgatcg	ccagttctgt	atgaacggtc	tggtctttgc	cgaccgcacg	ccgcatccag	5040
cgctgacgga	agcaaaacac	cagcagcagt	ccctgtatgt	ccgtttatcc	gggcaaacca	5100
tcgaagtgcg	cagcgaatac	ctgttccgtc	atagcgataa	cgagctcctg	cactggatgg	5160
tggcgctgga	tggtaagccg	ctggcaagcg	gtgaagtgcc	tctggatgtc	gctccacaag	5220
gtaaacagtt	gattgaactg	cctgaactac	cgcagccgga	gagcgccggg	caactctggc	5280
tcacagtacg	cgtagtgcaa	ccgaacgcga	ccgatgggtc	agaagccggc	cacatcagcg	5340
cctggcagca	gtggcgtctg	cgcgaaaacc	tcagtgtgac	gctccccgcc	gcgtcccacg	5400
ccatcccgcg	tctgaccacc	agcgaatggg	atttttgcat	cgagctgggt	aataagcgtt	5460
ggcaatttaa	ccgccagtcg	ggctttcttt	cacagatgtg	gattggcgat	aaaaaacaac	5520
tgtctgacgc	gctgcgcgat	cagttcaccc	gtgcaccgct	ggataacgac	attggcgtaa	5580
gtgaagcgac	ccgatttgac	cctaaccgct	gggtcgaaacg	ctggaaggcg	gcgggccatt	5640
accaggccga	agcagcgttg	ttgcagtgca	cggcagatac	acttgctgac	gcggtgctga	5700
ttacgaccgc	tcacgcgtgg	cagcatcagg	ggaaaacctt	atztatcagc	cggaaaacct	5760
accgatttga	tggtagtggg	caaatggcga	ttaccgttga	tgttgaagtg	gcgagcgata	5820
caccgcatcc	ggcgcggtat	ggcctgaact	gccagctggc	gcaggtagca	gagcgggtaa	5880
actggctcgg	attagggccg	caagaaaact	atccccgaccg	ccttactgcc	gcctgttttg	5940
accgctggga	tctgccattg	tcagacatgt	ataccccgta	cgtcttccccg	agcgaaaacg	6000
gtctgcgctg	cgggacgcgc	gaattgaatt	atggcccaca	ccagtggcgc	ggcgacttcc	6060
agttcaaacat	gacgcgctac	agtcaacagc	aactgatgga	aaccagccat	cgccatctgc	6120
tgacgcgga	agaaggcaca	tggctgaata	tcgacggttt	ccatatggggg	attgggtggag	6180
acgactcctg	gagcccgctc	gtatcgcgcg	aattacagct	gagcgccggg	cgctaccatt	6240

accagttggt	ctggtgtcaa	aaatagattc	tatagtgtca	cctaaatgct	agagctcgct	6300
gatcagcctc	gactgtgcct	tctagttgcc	agccatctgt	tgtttgcccc	tccccgtgc	6360
cttccttgac	cctggaaggt	gccactccca	ctgtcctttc	ctaataaaat	gaggaaattg	6420
catcgcatg	tctgagtagg	tgctattcta	ttctgggggg	tggggtgggg	caggacagca	6480
agggg						6485

<210> 4

<211> 7932

<212> DNA

<213> human

<400> 4

gcggccgctc	tggttatcca	ggcttctgaa	ggttcaagca	aagaaaggg	tacaacctta	60
aaaggagagc	gtccccgggt	atgggtagaa	gactgtcca	ccccgacccc	cagggtccct	120
aaccgtcttt	tccctgggcg	agtcagccca	atcacaggac	tgagagtgcc	tctttagtag	180
cagcaagcca	cttcgggacac	ccaaatggaa	cacctccagt	cagccctcgc	cgaccacccc	240
acccccctcca	tcctttttccc	tcagcctccg	attggctgaa	tctagagtcc	ctccctgctc	300
ccccctctct	ccccacccct	ggtgaaaact	gcgggcttca	gcgctgggtg	cagcaactgg	360
aggcgttggc	gcaccaggag	gaggctgcag	ctaggggagt	ccaggtgaga	gcaggccgac	420
gggaggggacc	cgcacatgca	aggaccgccc	cagggcgagg	atgcaagcct	tccccagcta	480
cagttttggg	aaaggatacc	agggcgctcc	tatatggggg	cgcggggaact	ggggaaagaa	540
ggtgctccca	ggtcagagg	ggagaggaag	gcagtgcggg	gtcacgggct	ttctccctgc	600
taacggacgc	tttcgaagag	tgggtgccgg	aggagaacca	tgaggaagga	catcaaggac	660
agcctttgg	ccccaaagctc	aaatcgcttt	agtgggtgcga	atagagggag	gaggtgggtg	720
gcaaactgga	gggagtcccc	agcgggtgac	ctcgtggctg	gctgggtgcg	gggcaccgca	780
ggtaagaaaa	ccgcaatgtt	gcgggagggg	actgggtggc	aggcgcgggg	gaggggaaag	840
ctagaaaagga	tgcgaggggag	cggagggggg	agggagcggg	agaatctcaa	ctggtagagg	900
aagattaaaa	tgaggaaata	gcatacagggt	ggggtagacc	aagccgggccc	tcagggaag	960
ggcgcaaagt	ttgtctgggt	gtgggcttag	gtgggctggg	tatgagattc	ggggcgccga	1020
aaacactgct	gcgctctctgc	caaatacagc	tacctctgta	tctagtctctg	ccaggcttct	1080
ccagccccag	ccccaatctt	tttctctagt	gttccccctt	ccctccctctg	aatctcaagc	1140
ccacactccc	tcctccataa	cccactgtta	tcaaataccaa	gtcatttgcc	acccaacaac	1200
catcaggagg	cggaaagcaga	cgggaggagt	ttgagatcaa	cttgggctac	atcacgagtt	1260
ccaggctcac	caaggcttct	taaggagacc	ttgtctctaa	aattaattaa	ttaattaatt	1320
aatagtcccc	tttctctgcc	acagaacctt	gggatctggc	tcctggctcg	agctcccccc	1380
accccaggct	gacattcact	gccatagccc	atccggaaat	cctagtctat	ttccccatgg	1440
atcttgaact	gcagagagaa	tggcagagt	gcccgcctctg	tgcaaaggat	gttcctagcc	1500
taggtggagc	tcgcgaactc	gcagactgtg	cctctcttgg	gcaaggacag	gctagacagc	1560
ctgccggtgt	gttgagctag	ggcactgtgg	ggaaggcaga	gaacctgtgc	agggcagcaa	1620
tgaacacagg	accagaaaac	tgcagcccta	ggaacactca	agagctggcc	atttgcaagc	1680
atctctggcc	tcctgtcttc	tcactcatgt	cccatgtctt	atacaggcct	ctgtggcacc	1740
tcgcttgcc	gatctcatcc	ctagccgtta	agctttctgc	atgacttatc	acttggggca	1800
taatgctgga	tacctaccat	tttcttagac	cccatcaaaa	tcctatttga	gtgtacggtt	1860
cggagaacct	catttatccg	gtaaatgtct	tttactctgc	tctcagggag	ctgaggcagg	1920
acatcctgag	atacattggg	agaggagata	cagtttcaat	aaaataatag	gttgggtgga	1980
ggtacatgcc	tataatgcca	ccactcagga	aatgggtggc	gcttcgtgag	tttgaggcca	2040
acccaagaaa	catagtga	ccctgtcagt	aaataagtaa	gcaagtattt	gagtatctac	2100
tatatgctag	ggctgacctg	gacattagg	gtcatcttct	gaacaaacta	gtgcttgagg	2160
gaggtatttg	gggtttttgt	ttgttttaag	gatctgaatg	agttccagag	actggctaca	2220
cagcgatatg	actgagctta	acacccctaa	agcatacagt	cagaccaatt	agacaataaa	2280
aggtatgtat	agcttaccaa	ataaaaaaat	tgtattttca	agagagtgtc	tgtctgtgta	2340
gccctggctg	ttcttgaact	cactctgtag	accaggctgg	cctggaaatc	catctgcctg	2400
cctctgcctc	tctgcctctc	tgcctctctg	cctctctctc	tgcctctctc	tgcctctctc	2460
tgccctctct	tgcctctctc	tgcctctctc	tgcctctctc	tgcctctctc	tgcctctctc	2520
cctctgcctc	ctggcctctg	gcctctgccc	tctgcctctc	ggcctctggc	ctctgcctct	2580
gcctcttgag	tgctggaatc	aaagggtgtg	gctctgtagg	tcttaagtcc	cagaagaaag	2640
taatgaagtc	acccagcagg	gaggtgctca	gggacacac	agacacacac	ccagacacac	2700
ggctccact	tccttggtct	tctctgagtg	gcaaaggacc	ttaggcagtg	tcactcccta	2760
agagaagggg	ataaagagag	gggctgaggt	attcatcatg	tgctccgtgg	atctcaagcc	2820
ctcaaggtaa	atggggaccc	acctgtccta	ccagctggct	gacctgtagc	tttccccacc	2880

acagaatcca	agtcggaact	cttggcacia	gcttggtacc	gccgccacca	tggcatcatc	2940
ctggccccct	ctagagctcc	aatcctccaa	ccagagccag	ctcttccctc	aaaatgctac	3000
ggcctgtgac	aatgctccag	aagcctggga	cctgctgcac	agagtgtctc	cgacatttat	3060
catctccatc	tgtttcttcg	gcctcctagg	gaaccttttt	gtcctgttgg	tcttccctct	3120
gccccggcgg	caactgaacg	tggcagaaat	ctacctggcc	aacctggccg	cctctgatct	3180
ggtgtttgtc	ttgggcttgc	ccttctgggc	agagaatatc	tgggaaccagt	ttactggcc	3240
tttcggagcc	ctcctctgcc	gtgtcatcaa	cggggtcatc	aaggccaatt	tgttcatcag	3300
catcttcttg	gtgggtggcca	tcagccagga	ccgtaccgc	gtgctggtgc	accctatggc	3360
cagccggagg	cagcagcggc	ggaggcaggc	cggggtcacc	tgcgtgctca	tctgggttgt	3420
ggggggcctc	ttgagcatcc	ccacattcct	gctgcgatcc	atccaagccg	tcccagatct	3480
gaacatcacc	gcctgcatcc	tgtcctctcc	ccatgaggcc	tggcactttg	caaggattgt	3540
ggagttaaat	attctgggtt	tctccttacc	actggctgcg	atcgtcttct	tcaactacca	3600
catcctggcc	tccctgcgaa	cgcgggagga	ggtcagcagg	acaagggtcg	ggggccgcaa	3660
ggatagcaag	accacagcgc	tgatcctcac	gctcgtggtt	gccttctctg	tctgctgggc	3720
cccttaccac	ttctttgcct	tcttgaatt	cttattccag	gtgcaagcag	tccgaggctg	3780
cttttgagg	gacttcattg	acctgggctt	gcaattggcc	aacttctttg	ccttactacta	3840
cagctccctg	aatccagtaa	tttatgtctt	tgtgggcccg	ctcttcagga	ccaaggctctg	3900
ggaactttat	aaacaatgca	cccctaaaag	tcttgcctca	atatcttcat	cccataggaa	3960
agaaatcttc	caacttttct	ggcgggaatta	atgcagctga	cggtagccgc	ggcccgggat	4020
ccgccccctc	ccctccccc	cccctaaccgt	tactggccga	agccgcttgg	aataaggccg	4080
gtgtgctgtt	gtctatatgt	tattttccac	catattgccg	tcttttgcca	atgtgagggc	4140
ccggaaccc	ggccctgtct	tcttgacgag	cattcctagg	ggtctttccc	ctctcgccaa	4200
aggaatgcaa	ggtctgttga	atgtcgtgaa	ggaagcagtt	cctctggaag	cttcttgaag	4260
acaaacaacg	tctgtagcga	ccctttgcag	gcagcggaac	ccccacactg	gcgacaggtg	4320
cctctgcggc	caaaagccac	gtgtataaga	tacacctgca	aaggcggcac	aaccccagtg	4380
ccacgtttgt	agttggatag	ttgtggaaag	agtcaaattg	ctctcctcaa	gcgtattcaa	4440
caaggggctg	aaggatgccc	agaaggtaac	ccattgtatg	ggatctgatc	tggggcctcg	4500
gtacacatgc	tttacatgtg	tttagtcgag	gttaaaaaaa	cgtctaggcc	ccccgaacca	4560
cggggacgtg	gttttcttct	gaaaaacacg	atgataatat	ggccacaacc	atgatagatc	4620
ccgtcgtttt	acaacgtcgt	gactgggaaa	accctggcgt	tacccaactt	aatcgccctg	4680
cagcacatcc	ccctttcgcc	agctggcgta	atagcgaaga	ggcccgccac	gatcgccctt	4740
cccaacagtt	gcgcagcctg	aatggcgaa	ggcgctttgc	ctggtttccg	gcaccagaag	4800
cgggtgccgga	aagctggctg	gagtgcgatc	ttcctgaggc	cgatactgtc	gtcgtccctt	4860
caaactggca	gatgcacggg	tacgatgcgc	ccatctacac	caacgtgacc	tatcccatta	4920
cggtaaatcc	cgggtttggt	cccacggaga	atccgacggg	ttgttactcg	ctcaccttta	4980
atgttgatga	aagctggcta	caggaaggcc	agacgcgaat	tatttttggat	ggcggttaact	5040
cggcgtttca	tctgtggtgc	aacgggcgct	gggtcgggta	cggccaggac	agtcgtttgc	5100
cgtctgaatt	tgacctgagc	gcattttttac	gcgccggaga	aaaccgcctc	gcggtgatgg	5160
tgtctgcctg	gagtgacggc	agttatcttg	aagatcagga	tatgtggcgg	atgagcggca	5220
ttttccgtga	cgtctcgttg	ctgcataaac	cgactacaca	aatcagcgat	ttccatgttg	5280
ccactcgctt	taatgatgat	ttcagccgcg	ctgtactgga	ggctgaagtt	cagatgtgcg	5340
gcgagttgcg	tgactaccta	cgggtaacag	tttcttttatg	gcaggggtgaa	acgcaggtcg	5400
ccagcggcac	cgcgcctttc	ggcggtgaaa	ttatcgatga	gcgtgggtgt	tatgccgatc	5460
gcgtcacact	acgtctgaac	gtcgaaaacc	cgaactgtg	gagcgccgaa	atcccgaatc	5520
tctatcgtgc	ggtggttgaa	ctgcacaccg	ccgacggcac	gctgattgaa	gcagaagcct	5580
gcgatgtcgg	tttccgcgag	gtgcggattg	aaaatggctc	gctgctgctg	aacggcaagc	5640
cgttgctgat	tcgaggcggt	aaccgtcacg	agcatcatcc	tctgcatggt	caggatcatgg	5700
atgagcagac	gatggtgcag	gatatcctgc	tgatgaagca	gaacaacttt	aacgccgtgc	5760
gctgttcgca	ttatccgaac	catccgctgt	ggtacacgct	gtgcgaccgc	tacggcctgt	5820
atgtggtgga	tgaagccaat	attgaaaccc	acggcatggt	gccaatgaat	cgtctgaccg	5880
atgatccgcg	ctggctaccg	gcgatgagcg	aacgcgtaac	gcgaatggtg	cagcgcgatc	5940
gtaatcacc	gagtgatgat	atctggtcgc	tggggaatga	atcaggccac	ggcgtaatc	6000
acgacgcgct	gtatcgctgg	atcaaatctg	tcatccttc	ccgcccgggtg	cagtatgaag	6060
gcggcgagc	cgacaccacg	gccaccgata	ttatttgccc	gatgtacgcg	cgcgtggatg	6120
aagaccagcc	cttcccggct	gtgccgaaat	gggccatcaa	aaaatggctt	tcgctacctg	6180
gagagacgcg	cccgtgatc	ctttgcgaat	acgcccacgc	gatgggtaac	agtcttggcg	6240
gtttcgctaa	atactggcag	gcgtttcgte	agtatccccg	tttacagggc	ggcttcgtct	6300
gggactgggt	ggatcagtcg	ctgattaaat	atgatgaaaa	cggcaaccgc	tggctcggtt	6360
acggcggtga	ttttggcgat	acgccgaacg	atcgccagtt	ctgtatgaac	ggtctggtct	6420
ttgccgaccg	cacgccgcat	ccagcgctga	cgggaagcaaa	acaccagcag	cagtttttcc	6480

```

agttccggtt atccggggcaa accatcgaag tgaccagcga atacctgttc cgtcatagcg 6540
ataacgagct cctgcactgg atggtggcgc tggatggtaa gccgctggca agcgggtgaag 6600
tgcctctgga tgtcgtctcca caaggtaaac agttgattga actgcctgaa ctaccgcagc 6660
cggagagcgc cgggcaactc tggctcacag tacgcgtagt gcaaccgaac gcgaccgcat 6720
ggtcagaagc cggccacatc agcgcctggc agcagtggcg tctggcgga aacctcagtg 6780
tgacgctccc cgccgcgtcc caccgcatcc cgcacttgac caccagcgaa atggattttt 6840
gcacgagct gggtaataag cgttggcaat ttaaccgcca gtcaggcttt ctttcacaga 6900
tgtggattgg cgataaaaaa caactgctga cgccgctgcg cgatcagttc acccgtgcac 6960
cgctggataa cgacattggc gtaagtgaag cgaccgcgat tgaccctaac gcctgggtcg 7020
aacgctggaa ggcggcgggc cattaccagg ccgaagcagc gttgttgtag tgcacggcag 7080
atacacttgc tgacgcggtg ctgattacga ccgctcacgc gtggcagcat caggggaaaa 7140
ccttatttat cagccggaaa acctaccgga ttgatggtag tggtaaatg gcgattaccg 7200
ttgatgttga agtggcgagc gatacacccg atccggcgcg gattggcctg aactgccagc 7260
tggcgagcgt agcagagcgg gtaaaactgg tcggattagg gccgcaagaa aactatcccg 7320
accgccttac tgccgcctgt tttgaccgct gggatctgcc attgtcagac atgtataccc 7380
cgtacgtctt cccgagcgaa aacggtctgc gctgcgggac gcgcgaattg aattatggcc 7440
cacaccagt ggcgcggcgac ttccagttca acatcagccg ctacagtcaa cagcaactga 7500
tggaaccag ccacgcgcat ctgctgcacg cggaagaagg cacatggctg aatatcgacg 7560
gtttccatat ggggattggt ggagacgact cctggagccc gtcagtatcg gcggaattac 7620
agctgagcgc cggtcgctac cattaccagt tggctctggtg tcaaaaatag attctatagt 7680
gtcacctaaa tgctagagct cgctgatcag cctcgactgt gccttctagt tgccagccat 7740
ctgttgtttg cccctcccc gtgccttcct tgaccctgga aggtgccact cccactgtcc 7800
tttctaata aaatgaggaa attgcatcgc attgtctgag taggtgtcat tctattctgg 7860
ggggtggggg gggcgaggac agcaaggggg aggatgggga agacaatagc aggcattgctg 7920
gggagcggcc gc 7932

```

<210> 5
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> oligonucleotide

<400> 5
 catcactgag cccaacacaaa 20

<210> 6
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> oligonucleotide

<400> 6
 tcacctcgag gactgcagac 20

<210> 7
 <211> 28
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> oligonucleotide

<400> 7
 gcggatcctg agctcctcct ctgctcgc 28

<210> 8

<211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> oligonucleotide

 <400> 8
 ctcgaggact gcagactcag 20

 <210> 9
 <211> 21
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> oligonucleotide

 <400> 9
 gtaagtaccg cctatagagt c 21

 <210> 10
 <211> 24
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> oligonucleotide

 <400> 10
 ctgcagaaaa gacccatgga aagg 24

 <210> 11
 <211> 39
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> oligonucleotide

 <400> 11
 gagtctgcag tcctcgaggt aagtaccgcc tatagagtc 39

 <210> 12
 <211> 42
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> oligonucleotide

 <400> 12
 tggcggcggg accaagcttc tgcagaaaag acccatggaa ag 42

 <210> 13
 <211> 42
 <212> DNA
 <213> Artificial Sequence

 <220>

<223> oligonucleotide

<400> 13

ctttccatgg gtcttttctg cagaagcttg gtaccgccgc ca

42

<210> 14

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<400> 14

gcgcggccgc tccccagcat gcctgctatt g

31

<210> 15

<211> 39

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<400> 15

gagtctgcag tcctcgaggt aagtaccgcc tatagagtc

39

<210> 16

<211> 31

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<400> 16

cggcggccgc cgatgtacgg gccagatata c

31

<210> 17

<211> 45

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<400> 17

gactctatag gcggtactta cctatagtga gtcgtattaa ttctg

45

<210> 18

<211> 45

<212> DNA

<213> Artificial Sequence

<220>

<223> oligonucleotide

<400> 18

cgaaattaat acgactcact ataggtaagt accgcctata gagtc

45

<210> 19
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 19
ccaacttttc tggcggaatt aatgcatcta gggcggccaa ttc 43

<210> 20
<211> 53
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 20
gtaaaacgac gggatctatc atgggtggcgg cggttggtgcaa gcttatcatc gtg 53

<210> 21
<211> 53
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 21
cacgatgata agcttgccaa ccgccgccac catgatagat cccgtcgttt tac 53

<210> 22
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 22
gcctcgagct atttttgaca ccagaccaac tg 32

<210> 23
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 23
catttaggtg acactataga atctatTTTTT gacaccagac caactg 46

<210> 24
<211> 46
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 24
cagttggtct ggtgtcaaaa atagattcta tagtgtcacc taaatg 46

<210> 25
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 25
gaattggccg ccctagatgc attaattccg ccagaaaagt tgg 43

<210> 26
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 26
ggcatcatga tagatcccgt cgttttac 28

<210> 27
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 27
tactgtgagc cagagttgcc 20

<210> 28
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 28
gcgcggccgc tctggttatc caggcttctg 30

<210> 29
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 29
ggtggcggcg gtaccaagct tgtgccaaga gttccgactt g 41

<210> 30
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 30
caagtcggaa ctcttggcac aagcttgga cgcgccac c 41

<210> 31
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 31
tgcttgacc tggaataag 19

<210> 32
<211> 19
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 32
tgcttgacc tggaataag 19

<210> 33
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 33
gagtctgcag tcctcgagaa gc 22

<210> 34
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> oligonucleotide

<400> 34
tgagtctgca gtcctcgaga ag 22

<210> 35
<211> 25
<212> DNA
<213> Artificial Sequence

<220>
 <223> oligonucleotide

 <400> 35
 ctccaatcct ccaaccagag ccagc 25

 <210> 36
 <211> 25
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> oligonucleotide

 <400> 36
 tccaatcctc caaccagagc cagct 25

 <210> 37
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> oligonucleotide

 <400> 37
 aatctcgggt acgtgttccg 20

 <210> 38
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> oligonucleotide

 <400> 38
 ttggccaggt agatttctgc 20

 <210> 39
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> oligonucleotide

 <400> 39
 aatctcgggt acgtgttccg 20

 <210> 40
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> oligonucleotide

 <400> 40

ttggccaggt agatttctgc

20

<210> 41

<211> 1707

<212> DNA

<213> rat

<400> 41

gtagcctgcc	tccgatattt	gttagaacia	cggttccccg	ccacctacca	actgtttatg	60
ttttctctaa	caaaaaccag	accggccgct	gggcctgata	cctgagttca	gtcaccaaga	120
cccacgtggc	agaaggagag	aactgacttc	tgcatattat	cctccaacac	acacacacac	180
acacacacac	acacacacac	acacacacac	acacactaaa	ataaataaat	agtctgggct	240
tggtggcaca	ttgagaactt	acctcagaaa	aaaggtaagt	agataaaagta	aaactaaaat	300
ggagtggagtc	acactggagt	tccatgttac	caaattaaaa	ctagctttct	gaccttctga	360
gaaaccagga	cagaaagagg	tgaaggccac	attttctagc	catgccaaact	gcagcaaaca	420
taactctgtt	ctggctgcca	ttgtccttat	gaaaagtaag	caggagggat	ctgatctatt	480
aaccagctag	ctctgtgctt	ccctcctctt	ctcccaacct	cccaaggaaa	acatactccg	540
tccttttctt	ttgttttatt	cctgtcttct	gtctaggaaa	tcactcccct	ccaaggcgct	600
agaacacatt	ctggcttaca	gaatgaagtt	ttaccacaatt	ctagaatcac	aaaatatagc	660
caacgtaaac	cttgaatgtg	atctaattgg	tctaagaggc	agaaatgaga	tgaagaaaaa	720
aactgccgac	atagatttca	gtctatggga	tgatgggcac	ataaacaata	agaagaaagt	780
gccagacagg	ggtaggtgct	ctaaatacaa	gataaattag	agcagggtga	gaagatggta	840
ctggggattg	gaggggagac	tgcttttaggc	agggtatggg	aaaggatatgc	cccctgagag	900
aggatgttca	tttttagcac	ttgaatttta	ttttagtgtg	tgtgtatgca	tgtgccacag	960
caaagtgtata	gaagtaaaag	gagaccttga	gagaagtggg	tcactcctcc	catgttgggtc	1020
ttgggatcga	agtcagggtg	ttagacttga	caggaagttt	ctctccccag	tgagctgtct	1080
caccagccca	aagggtggca	acatttttgc	tgagacctaa	ataaaggaca	tgcgtcagtt	1140
cagaaaccac	agatatctga	tcaaccaagc	tcctgcagtc	tcacctcatc	ttcctctcag	1200
ccacactggc	ccttcagtggt	ccccagcagt	ccccgaggtg	ggtgggtcaa	aatgtttatg	1260
tggttacctt	tcatcaactc	cttccccatc	tccagccccg	gccagaccct	ccagggcaaa	1320
ctgaggcctc	atctgagctc	ctcctctgct	cgcccaatcc	ttccaacccc	ctatggtgggt	1380
attgtctgtt	taccctatag	gacatcctat	agggtaaaca	gacaatagac	cataggacaa	1440
caggcaggag	catgcctgct	attgtcctcc	cttgtcctcc	ctgccatcct	aaagctggca	1500
ggtggctggt	ggtatatgga	ggatgtagct	gggccaggga	aaagatcctg	cactaaaaat	1560
ctgaagctaa	aaataacagg	acacgggatg	gaggagctca	ggtgggtatg	ctgacacaga	1620
aaatgtctgc	tcctgtatgg	gacatttggc	cctcttctcc	aaatataaga	caggatgagg	1680
cctagctttt	gctgctccaa	agtttta				1707